

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

126. *Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-bades regimen from rilpivirine or other regimens.* P. Maggi, E.D. Ricci, S. Cicalini, **G.F. Pellicanò**, B.M. Celesia, F. Vichi, A. Cascio, E. Sarchi, G. Orofino, N. Squillace, G. Madeddu, G.V. De Socio, O. Bargiacchi, C. Molteni, A. Masiello, A. Saracino, B. Menzaghi, K. Falasca, L. Taramasso, A. Di Biagio, P. Bonfanti. *BMC Infectious Disease* **2023 Apr 14**;23(1):227. Doi: 10.1186/s12879-023-08191-2. PMID: 3705996. MEDLINE:3705996. eISSN: 1471-2334. NLM Unique ID: 100968551.

125. *Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study.* A. De Vito, E. Ricci, B. Menzaghi, Giancarlo Orofino, Canio Vito Martinelli, N. Squillace, L. Taramasso, G.V. De Socio, C. Molteni, L. Valsecchi, C. Costa, B.M. Celesia, G. Parruti, **G.F. Pellicanò**, E. Sarchi, A. Cascio, G. Cenderello, K. Falasca, A. Di Biagio, P. Bonfanti and G. Madeddu. *Viruses* **2023 Mar 10**; 15(3),720. Doi: 10.3390/v15030720. PMID: 36992429. eISSN: 1999-4915. NLM Unique ID: 101509722. SCOPUS: 2-s2.0-85151200056.

124. *Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort.* L.A. Nicolini, B. Menzaghi, E. Ricci, E. Pontali, G. Cenderello, G. Orofino, A. Cascio, **G.F. Pellicanò**, L. Valsecchi. C. Molteni, F. Vichi, P. Bonfanti and A. Di Biagio. *Frontiers in Medicine*. **2023 January 27**;10:1086012. Doi: 10.3389/fmed.2023.1086012. eCollection 2023. PMID: 36778739. WOS:000930649800001. SCOPUS: 2-s2.0-85147772275.

123. *Diagnosis, Treatment, and Prevention of HIV Infection among Detainees: A Review of the Literature.* Russotto Y., Micali C., Laganà N., Marino A., Campanella E., Celesia B.M., **Pellicanò G.F.**, Venanzi Rullo E., Nunnari G. *Healthcare (Basel)*. **2022 Nov 27**;10(12):2380-2391. Doi: 10.3390/healthcare10122380. PMID: 36553904. PMC9777892. WOS:000900882200001. SCOPUS: 2-s2.0-85128423467.

122. *Safety and efficacy of switching people with HIV to dual treatment with 3TC/DTG and RPV/DTG in real life: results from the SCOLTA cohort.* De Vito, A; Ricci, E; Orofino, G; Taramasso, L; Sarchi, E; Costa, C; **Pellicanò, G**; Pagnucco, L; Menzaghi, B; De Socio, G; Celesia, B; Piconi, S; Maggi, P; Bonfanti, P; Madeddu, G. Contributo in atti di Convegno: HIV Drug Therapy - Glasgow **oct 2022**. *Journal of the International AIDS Society* 25(6) – 83-85. WOS:000870695800106.

121. *Liver enzyme variation after switching to emtricitabine/tenofovir alafenamide/bictegravir is associated with glucose in a real-life cohort.* Squillace, N; Ricci, E; Maggi, P; Menzaghi, B; De Socio, G; Orofino, G; Celesia, B; Bandera, A; Salomoni, E; Di Biagio, A; Taramasso, L; Piconi, S; Sarchi, E; Valsecchi, L; **Pellicanò, G**; Cenderello, G; Bonfanti, P. Contributo in atti di Convegno: HIV Drug Therapy - Glasgow **oct 2022**. *Journal of the International AIDS Society* 25(6) – 151-153. WOS:000870695800181.

120. *With or without TAF? What is the difference? Data from a real-life setting.* Squillace, N; Taramasso, L; Orofino, G; Maggi, P; Menzaghi, B; Piconi, S; De Socio, G; Sarchi, E; Valsecchi, L; Celesia, B; Vichi, F; **Pellicanò, G**; Cenderello, G; Falasca, K; Ricci, E; Di Biagio, A; Bonfanti, P. Contributo in atti di Convegno: HIV Drug Therapy - Glasgow **oct 2022**. *Journal of the International AIDS Society* 25(6) – 153-154. WOS:000870695800181.

119. *Humoral immunogenicity to third dose SARS-COV-2 mRNA vaccine in people living with HIV (PLWHIV) by current CD4 count and CD4/CD8 ratio.* Vergori, A; Cozzi-Lepri, A; Tavelli, A; Giannella, M; Cicalini, S; Marconi, L; Yellenki, V; Meschi, S; **Pellicano, G**; Caroccia, N; Matusali, G; Latini, A; Lichtner, M; Lo Caputo, S; Fusco, F;

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Marchetti, G; Tacconelli, E; Antinori, A; Monforte, Ad. Contributo in atti di Convegno: HIV Drug Therapy - Glasgow **oct 2022**. Journal of the International AIDS Society 25(6) – 208-209. WOS:000870695800259.

118. *Metabolic and hepatic safety in ART-experienced PLWHIV switching to a DOR-based regimen versus rilpivirine: data from real life*. Maggi P., Ricci E., Martinelli C., Squillace N., De Socio G., Orofino G., Masiello A., Menzaghi B., Vichi F., Pistara E., Valsecchi L., Bitti A., Calza L., **Pellicanò G.**, Cascio A., Taramasso L., Sarchi E., Falasca K., Bargiacchi O., Cenderello G., Di Biagio A., Bonfanti P. Contributo in atti di Convegno: HIV Drug Therapy - Glasgow **oct 2022**. Journal of the International AIDS Society 25(6) – 68-69. WOS:000870695800089.

117. *Trajectories of CD4+/CD8+T cells ratio 96 weeks after switching to dolutegravir-based two drug regimens. Results from a multicenter prospective cohort study*. Lucia Taramasso, Antonio Falletta, Elena Ricci, Giancarlo Orofino, Nicola Squillace, Barbara Menzaghi, Giuseppe Vittorio De Socio, Chiara Molteni, **Giovanni Francesco Pellicanò**, Roberto Gulminetti, Giordano Madeddu, Eleonora Sarchi, Francesca Vichi, Benedetto Maurizio Celesia, Paolo Bonfanti, Antonio Di Biagio. Infect. Dis. Rep. **2022 Oct 22**, 14(11):2315-2326. Doi: 10.3390/v14112315. PMID: 36366413. eISSN: 2036-7449. PMCID: PMC9696165. WOS:000881564200001. SOPS: 2-s2.0-85141672313.

117. *Efficacy of Covid-19 vaccination in people living with HIV: a public health fundamental tool for the protection of patients and the correct management of infection*. A. Facciola, S. D'Amato, S. Calimeri, D. Lo Giudice, C. Micali, Y. Russotto, E. Venanzi Rullo, G. Nunnari, R. Squeri, **G.F. Pellicanò**. Infect. Dis. Rep. **2022 Oct 17**, 14(5), 784-793. Doi: 10.3390/ids14050080. PMID: 36286201 eISSN: 2036-7449. PMCID: PMC9602118. WOS:000873074800001. SOPS: 2-s2.0-85140457841.

116. *Impact of the COVID-19 pandemic on HPV vaccination coverage in the general population and in PLWH*. S. D'Amato, G. Nunnari, G. Trimarchi, A. Squeri, A. Cancellieri, R. Squeri, **G.F. Pellicanò**. European Review for Medical and Pharmacological Sciences **2022. 15 oct**; 26(19): 7285-7289. doi:10.26355/eurrev_202210_29922. PMID: 36263540. ISSN: 2284-0729/1128-3602. SCOPUS: 2-s2.0-85140307901. WOS:000884727300001.

115. *Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity? Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profile di comorbidità differenti?* V. Zollo, B. Menzaghi, C. Molteni, N. Squillace, L. Taramasso, I. De Luca, G. Gamboni, D. Altobelli, M. Guastavigna, G. Madeddu, F. Vichi, A. Cascio, E. Sarchi, **G.F. Pellicanò**, C. Martinelli, B.M. Celesia, L. Valsecchi, R. Gulminetti, G. Cenderello, A. Parisini, L. Calza, K. Falasca, A. Di Biagio, P. Bonfanti, G. Orofino, P. Maggi, for the CISA Study Group. BMC Infectious Diseases. **2022 Sep 23**. 22:745. ISSN: 1471-2334. PMID: 36151508. Doi: 10.1186/s12879-022-07739-y. WOS:000857311400001. SCOPUS: 2-s2.0-85138460675.

114. *HIV and Mediterranean Zoonoses: a review of the literature*. Y. Russotto, C. Micali, G.F. Pellicanò, G. Nunnari, E. Venanzi Rullo. Infect. Dis. Rep. **2022 Sep 16**, 14(5), 694-709. Doi: 10.3390/ids14050075. PMID: 36136825. eISSN: 2036-7449. WOS:000873100480001. SOPS: 2-s2.0-85140795485.

113. *Thyroid diseases and thyroid asymptomatic dysfunction in People Living With HIV*. C. Micali, Y. Russotto, B.M. Celesia L. Santoro, A. Marino, , G.F. Pellicanò, G. Nunnari, E. Venanzi Rullo. Infect. Dis. Rep. **2022 Sep 1**,

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

14(5), 655-667. Doi: 10.3390/idr14050071. PMID: 36136821. eISSN: 2036-7449. PMID: 36136821. PMCID: PMC9498502. WOS:000873232300001. SOPS: 2-s2.0-85140603815.

112. *Splenic abscesses in childhood brucellosis: a case-based review*. P. Pavone, C. Gulizia, S. D'amico, P. Grassi, G. La Rosa, R. Leotta, A. Basile, S. Palmucci, P.V. Foti, G. Belfiore, L. Marino, **G.F. Pellicanò**, G. Pulvirenti. *European Review for Medical and Pharmacological Sciences* **2022**; 26(13): 4863-4871. doi: 10.26355/eurrev-_202007_29211. PMID: 35856378. ISSN: 2284-0729/1128-3602. WOS:000837256500038. SCOPUS: 2-s2.0-85134196360.

111. *Humoral immunogenicity to SARS-CoV-2 mRNA vaccine third additional/booster shot in people living with HIV (PLWH) by current CD4 count*. A. Antinori, A. Cozzi-Lepri, A. Vergori, A. Tavelli, M. Giannella, S. Cicalini, L. Marconi, V. Yellenki, S. Meschi, **G.F. Pellicanò**, N. Carroccia, G. Mutusali, A. Latini, M. Lichtner, S. Lo Caputo, F.M. Fusco, G. Marchetti, E. Tacconelli, A. d'Arminio Monforte for the VAXICONA-ORCHESTRA Study Group. *ICAR 2022*, Bergamo 14-16/06/2022- Poster.

110. *Poor humoral immunogenicity to SARS-CoV-2 vaccination in people living with HIV(PLWH) with low CD4 count*. A. Vergori, A. Cozzi-Lepri, M. Giannella. A. Tavelli, A.M. Azzini, L. Marconi, S. Cicalini, A. Rodanò, Silvia Meschi, M. Fusto, A. Sartor, G. Matusali, S. Piconi, **G.F. Pellicanò**, A. Cascio, G. Levy-Hara, A. Costantini, G. Madeddu, G. Marchetti, P. Viale. E. Tacconelli, A. d'Arminio Monforte, A. Antinori for the VAXICONA-ORCHESTRA Study Group. *ICAR 2022*, Bergamo 14-16/06/2022- Poster.

109. *Pulmonary Kaposi Sarcoma without Respiratory Symptoms and Skin Lesions in an HIV-Naïve Patient: A Case Report and Literature Review*. C. Micali, Y. Russotto, A. Facciolo, A. Marino, B.M. Celesia, E. Pistrà, G. Caci, G. Nunnari, **G.F. Pellicanò**, E. Venanzi Rullo. *Infect, Dis. Rep.* **2022**, 14(2), 228-242. (IF: Doi: 10.3390/idr14020028. PMID: 35447880. eISSN: 2036-7449. PMCID: PMC9025598. WOS:000785076800001. SOPS: 2-s2.0-85128423467.

108. *Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV*. C. Micali, Y. Russotto, G. Caci, M. Ceccarelli, A. Marino, B.M. Celesia, **G.F. Pellicanò**, G. Nunnari, E. Venanzi Rullo. *Infect, Dis. Rep.* **2022**, 14, 43-55. Doi: 10.3390/idr14010006. PMID: 35076514. PMCID: PMC8788283. SCOPUS: 2-s2.085123059814. WOS:000770234600001.

107. *Durability of Dolutegravir-Based Regimens: a 5-year prospective observational Study*. L. Taramasso, A. De Vito, E.D. Ricci, G. Orofino, N. Squillace, B. Menzaghi, C. Molteni, R. Gulminetti, G.V. De Socio, **G.F. Pellicanò**, E. Sarchi, B.M. Celesia, L. Calza, S. Rusconi, L. Valsecchi, C.V. Martinelli, A. Cascio, P. Maggi, F. Vichi, G. Angioni, G. Guadagnino, G. Cenderello, C. Dentone, A. Bandera, K. Falasca, P. Bonfanti, A. Di Biagio, G. Madeddu, Behalf of the CISA Study Group. *AIDS Patient Care STDS*. (IF: 5,944). **2021 Sep**;35(9):342-353. Doi: 10.1089/apc.2021.0089. PMID: 34524918. WOS:000696031000002. SCOPUS: 2-s2.0-85115292682.

106. *Management care improvement of people living with HIV: definition of a tareted clinical patway in a University Hospital of South Italy*. S. D'Amato, **G.F. Pellicanò**, G. Nunnari, F. Fedele, F. Mazzitelli, F. D'Andrea, D. Maisano, R. Squeri, C. Genovese. *Acta Biomed* **2021**; Vol. 92, N. 4: e2021244. ISSN: 0392-402. eISSN: 2531-6745. PMID: 34487078. Doi: 1023750/abm.v92i4.11425. SCOPUS: 2-s2.0-85114463609.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

105. *How Much Does HIV Positivity Affect the Presence of Oral HPV? A Molecular Epidemiology Survey.* Visalli, G.; Di Pietro, A.; Currò, M.; Pruiti Ciarello, M.; D'Andrea, F.; Nunnari, G.; **Pellicanò, G.F.**; Facciola, A. *Int. J. Environ. Res. Public Health* **2021**, *18*, 8999-9010. (IF: 4,614). PMID: 34501585. <https://doi.org/10.3390/ijerph18178999>. SCOPUS: 2-s2.0-85113457171. WOS:000694192400001.

104. *New generation biologics for the treatment of psoriasis arthritis. State of the art and cosideration about the risk of infection.* M. Ceccarelli, M. Venanzi Rullo, M. Berretta, **G.F. Pellicanò**, G. Nunnari, C. Guarneri, B. Cacopardo. *Dermatologic Therapy*. 2021. Early View. Vol. 34 (1), **2021-Jan**: e14660. 1-7. Published: 25 DEC **2020**. (IF: 3,858). Doi: 10.1111/dth.14660. eISSN: 1529-8019. ISSN: 1396-0296. NLM Unique ID: 9700070. PMID: 33301216. WOS:000601837200001. SCOPUS: 2-s2.0-85098084626.

103. *The effect of switching from Tenofovir disoproxil fumarate (TDF) to Tenofovir alafenamide (TAF) on liver enzyme, glucose and lipid profile.* N. Squillace, E. Ricci, B. Menzaghi, G.M. Migliorino, G.V. De Socio, S. Passerini, C. Martinelli, M. S. Mameli, P. Maggi, P. K. Falasca, L. Cordier, B.M. Celesia, E. Salamoni, A. Di Biagio, **G.F. Pellicanò**, P. Bonfanti, for the CISAI Study Group: G. Nunnari. *Drug Design, Development and Therapy* **2020**; **15 dec 2020**; 14:5515-5520. (IF: 4,319). Doi: 10.2147/DDDT.S274307. eCollection 2020. ISSN: 1177-8881. PMID: 33364747. PMCID: PMC7751319. NLM Unique ID: 101475745. WOS:000601316600001. SCOPUS: 2-s2.0-85098183734.

102. *Definition of a novel vaccination pathway in PLWHA: experience of a Southern University Hospital.* S. D'Amato, **G.F. Pellicanò**, C. Genovese, F. Mazzitelli, F. D'Andrea, R. Squeri. Poster nella sessione DP Infectious diseases (malaria, TB, AIDS) From the 16th European Public Health Conference - EUPHA 2020 – Roma 12-16 October **2020**. *European journal of Public Health*. Vol 30(5), Pages: V841-V841. September 2020, ckaa166.837. (IF: 4,424). doi: 10.1093/eurpub/ckaa166.837. ISSN: 2421-4248, eISSN: 1464-360X. ISSN: 1101-1262. https://academic.oup.com/eurpub/issue/30/Supplement_5. WOS:000605268703445. https://academic.oup.com/eurpub/article/30/Supplement_5/ckaa166.837/5914965.

101. *Vitamin D status modulates inflammatory response in HIV+ subjects: evidence for involvement of autophagy and TG2 expression in PBMC.* M. Currò, G. Visalli, **G.F. Pellicanò**, N. Ferlazzo, M.G. Costanzo, F. D'Andrea, D. Caccamo, G. Nunnari, R. Ientile. *Int. J. Mol. Sci.* **21(20)**, 7558; (IF: 6,208). doi: 10.3390/ijms21207558. – ISSN: 1422-0067 on 13 October **2020**. <https://www.mdpi.com/1422-0067/21/20/7558>. ISSN: 1422-0067; eISSN: 1661-6596. PMID: 33066266. SCOPUS: 2-s2.0-85092483935. WOS:000585534900001.

100. *Epidemiology of the new HIV infections in a large university hospital of Southern Italy: the importance of increasing the culture of the HIV screening test in the prevention of late diagnosis.* Epidemiologia delle nuove infezioni da HIV in un grande ospedale universitario del Sud Italia: l'importanza di aumentare la cultura del test di screening dell'HIV nella prevenzione delle diagnosi tardive. A. Facciola, G. Visalli, G. Antonuccio, F. Fedele, G. Nunnari, **G.F. Pellicanò**, I. Picerno, A. Di Pietro. *Epidemiol. Prev.* **2020**; *44(4)*. 235-242. (IF: 1,293). doi: 10.19191/EP20.4.P235.053. PMID: 32921029. NLM Unique ID: 8902507. ISSN: 1120-9763, 2385-1937. WOS:000575436900008. SCOPUS: 2-s2.0-85090872390.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

99. *Transmission mode associated with coronavirus disease 2019: a review.* F. Vella, P. Senia, M. Ceccarelli, E. Vitale, H. Maltezou, R. Taibi, A. Lleshi, E. Venanzi Rullo, **G.F. Pellicanò**, V. Rapisarda, G. Nunnari, C. Ledda. *European Review for Medical and Pharmacological Sciences* **2020** Apr; 24(14): 7889-7904. (IF: 3,784). doi: 10.26355/eurrev_202007_22296. PMID: 32744718. NLM Unique ID: 9717360. ISSN: 2284-0729/1128-3602. WOS:000555882500036. SCOPUS: 2-s2.0-85089114936.

98. *Editorial – Coronavirus disease 2019 and people living with HIV: clinical considerations.* M. Ceccarelli, G. Nunnari, B.M. Celesia, **G.F. Pellicanò**, E. Venanzi Rullo, M. Berretta, B. S. Cacopardo. *European Review for Medical and Pharmacological Sciences* **2020** Apr; 24(13): 7534-7539. (IF: 3,784). doi: 10.26355/eurrev_202007_21928. PMID: 32706096. NLM Unique ID: 9117360. ISSN: 1128-3602/2284-0729. WOS:000551170100040. SCOPUS: 2-s2.0-85088497364.

97. *Factors associated with weight gain in people treated with Dolutegravir.* Taramasso L., Bonfanti P., Ricci E., Orofino G., Squillace N., Menzaghi B., De Socio G.V., Madeddu G., **Pellicanò G.F.**, Pagnucco L., Celesia B.M., Calza L., Conti F., Martinelli C., Valsecchi L., Cascio A., Bolla C., Maggi P., Vichi F., Dentone C., Angioni G., Mastroianni A., Falasca K., Cenderello G., Di Biagio A. *Open Forum Infectious Diseases*, Volume 7. Issue 6, June 2020, ofaa195, doi: 10.1093/ofid/ofaa195. 26 May **2020**. EISSN: 2328-8957. PMID: 32577427. PMCID: PMC7295329. WOS:000565181000028. SCOPUS: 2-s2.0-85086344911.
<https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofaa195/5846085>.

96. *Physician Attitudes and Perceptions of Complementary and Alternative Medicine (CAM): A Multicentre Italian Study.* Massimiliano Berretta, Luca Rinaldi, Rosaria Taibi, Paolo Tralongo, Alberto Fulvi, Vincenzo Montesarchio, Giordano Madeddu, Paolo Magistri, Sabrina Bimonte, Marco Trovò, Patrizia Gnagnarella, Arturo Cuomo, Marco Cascella, Arben Lleshi, Guglielmo Nasti, Sergio Facchini, Francesco Fiorica, Raffaele Di Francia, Giuseppe Nunnari, **Giovanni Francesco Pellicanò**, Aurelio Guglielmino, Marco Danova, Sabrina Rossetti, Alfonso Amore, Anna Crispo and Gaetano Facchini. *Frontiers in Oncology*. *Front. Oncol.* 2020 Apr 28; 10:594. Doi: 10.3389/fonc.2020.00594. eCollection **2020**. (IF: 5,738). PMID: 32411599. PMCID: PMC7202223. ISSN: 2234-943X. NLM Unique ID: 101568867. WOS:000535605600001. SCOPUS: 2-s2.0-85084546395.

95. *Non-AIDS defining cancers: a comprehensive update on diagnosis and management.* M. Ceccarelli, E. Venanzi Rullo, M.A. Marino, F. D'Aleo, **G.F. Pellicanò**, F. D'Andrea, A. Marino, B. Cacopardo, B.M. Celesia, G. La Rocca, M. Di Rosa, F. Condorelli, M. Berretta, G. Nunnari. *European Review for Medical and Pharmacological Sciences* **2020** Apr; 24(7): 3849-3875. (IF: 3,784). doi: 10.26355/eurrev_202004_20852. PMID: 32329861. ISSN: 1128-3602/2284-0729. WOS:000528789200053. SCOPUS: 2-s2.0-85084030860.

94. *Hepatitis B virus infection and hepatocellular carcinoma in PLWH: epidemiology, pathogenesis and treatment.* D'Andrea F., Venanzi Rullo E., Marino A., Moscatt V., Celesia B.M., Cacopardo B., Condorelli F., La Rocca G., Di Rosa M., **Pellicanò G.F.**, Nunnari G., Ceccarelli M. *WCRJ* **2020**; 7: e1537. doi: 10.32113/wcrj_20203_1537. WOS:00051844440001.

93. *When the eye does not see, the bone can grieve: An unusual presentation of secondary syphilis.* Vaccaro M., Marafioti I., Nunnari G., **Pellicanò G.F.**, Vaccaro F., Trombetta C.J., Cannavò S.P. *Indian J Dermatol Venereol Leprol.* 86(2) March-April 2020: 184-186. **2020** Feb 07. Doi: 10.4103/ijdv.IJDVL_513_19. PMID:

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

32031111. NLM Unique ID: 7701852. ISSN: 0973-3922. LETTER TO THE EDITOR. SCOPUS: 2-s2.0-85081396663. WOS:000564170600012.

92. *Epstein barr virus related cancer in people living with HIV: a review of the literature.* F. D'Andrea, E. Venanzi Rullo, A. Facciola, M. Di Rosa, F. Condorelli, A. Marino, B. Cacopardo, **G.F. Pellicanò**, G. Nunnari, M. Ceccarelli. WCRJ **2020**; 7: e1512. doi: 10.32113/wcrj_20203_1512. WOS:000518434100001.

91. *Malignant melanoma in HIV: epidemiology, pathogenesis and management.* A. Facciola, E. Venanzi Rullo, M. Ceccarelli, F. D'Andrea, M.G. Coco, Cristina Micali, B. Cacopardo, A. Marino, S.P. Cannavò, M. Di Rosa, F. Condorelli, **G.F. Pellicanò**, C. Guarneri, G. Nunnari. Dermatol Ther, ePUB: 2019 Nov 26: e13180, Vol. 32(6) pag. 1-7. Published: **2020** Jan: 33(1), (IF: 3,858). doi: 10.1111/dth.13180. ISSN: 1529-8019. PMID: 31770477. WOS:000513844600034. SCOPUS: 2-s2.0-85076373390.

90. *Efficacy, safety and tolerability of dolutegravir-based combination antiretroviral therapy in clinical practice in HIV-infected patients: results from a multicenter study.* A. De Vito, G. Caruana, F. Clark, G. Nunnari, **G.F. Pellicanò**, G. Angioni, A. Freedman, A. Babudieri, G. Madeddu. INFECT DIS TROP MED **2019**; 5:e565. Doi: 10.32113/idtm_201912_565. ISSN: 2379-4054.

89. *Measles, Mumps, Rubella and Chickenpox epidemic and vaccination in Eastern Sicily: an epidemiologic study on seroconversion.* A. Facciola, G. D'Andrea, R. Cuffari, **G.F. Pellicanò**, G. Visalli, A. Di Pietro. INFECT DIS TROP MED **2019**; 5:e571. Doi: 10.32113/idtm_201912_571. ISSN: 2379-4054.

88. *Bone disease in HIV infection: an overview of pathogenesis, clinical manifestations and treatment.* F. Maimone, F. D'Andrea, A. Facciola, E. Venanzi Rullo, M.R. Lo Presti, G. Visalli, **G.F. Pellicanò**. INFECT DIS TROP MED **2019**; 5:e567. Doi: 10.32113/idtm_201912_567. ISSN: 2379-4054.

87. *Kaposi's Sarcoma and Psoriasis in a naïve HIV-positive patient: a case report.* F. D'andrea, A. Facciola, M.G. Coco, C. Micali, I. Paolucci, D. Maranto, M.R. Lo Presti Costantino, D. Larnè, P. Mondello, **G.F. Pellicanò**. INFECT DIS TROP MED **2019**; 5:e569. Doi: 10.32113/idtm_201912_569. ISSN: 2379-4054.

86. *Sinus bradycardia in a patient with bacterial meningitis in therapy with IVIg: a case report.* D'Andrea F., Ceccarelli M., Facciola A., Paolucci I.A., Maranto D., Lo Presti Costantino M.R., Spicola D., Larnè D., Venanzi Rullo E., Mondello P., **Pellicanò G.F.** Infectious Diseases & Tropical Medicine **2019**; 5: e539. Doi: 10.32113/idtm_20199_539. ISSN: 2379-4054.

85. *Pasturella multocida septic shock in an immunocompromised woman.* Larnè D., D'andrea F., Facciola A., Paolucci I.A., Ceccarelli M., Venanzi Rullo E., **Pellicanò G.F.** Infectious Diseases & Tropical Medicine **2019**; 5: e541. Doi: 10.32113/idtm_20199_541. ISSN: 2379-4054

84. *Malattie Infettive e Tropicali per Studenti e Medici di Medicina Generale.* G. Borgia, G.B. Gaeta, I. Gentile, N. Coppola, con l'apporto di: L. Alessio, G. Angarano, S. Babudieri, A. Bartoloni, A. Borgia, F. Borrelli, G. Brancaccio, A.R. Buonomo, B.S. Cacopardo, A. Cascio, C. Contini, S. Esposito, M. Fasano, M. Foggia, M. Gatti, V. Gentile, M. Macera, P. Maggi, A.E. Maraolo, A. Marino, C.M. Mastroianni, C. Mussini, G. Nunnari, L. Onorato,

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

M. Pacenti, **G.F. Pellicanò**, B. Pinchera, G. Pipitone, M.A. Pisaturo, C. Sagnelli, T.A. Santantonio, A. Santoro, A. Saracino, M. Spaziante, M. Spinnici, M. Stanzione, G. Stornaiuolo, G. Taliani, G. Tosone, C. Torti, P. Viale, L. Zammarchi, E. Zappullo. II Edizione **2019**. EDIZIONI IDELSON GNOCCHI 1908 Srl - NAPOLI. www.idelsongnocchi.it. ISBN: 9788879476959.

83. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results a large multicentre observational prospective cohort (SCOLTA). L. Taramasso, E. Ricci, A. Cascio, L. Valsecchi, B. Menzaghi, N. Squillace, P. Maggi, G. V. De Socio, C. Dentone, G. Madeddu, **G.F. Pellicanò**, L. Calza, G. Amgioni, P. Bonfanti, A. Di Biagio. *AIDS Research and Therapy*. (IF: 2,846). **2019** Aug 26, 16 (1);21. Doi: 10.1186/s12981-019-0236-0. PMID: 31451115.PMCID: PMC6710858. WOS:000482884000001. SCOPUS: 2-s2.0-85071637093.

82. The new era of vaccines: the “nanovaccinology”. A. Facciola, G. Visalli, P. Laganà, V. La Fauci, R. Squeri, **G.F. Pellicanò**, G. Nunnari, M. Trovato, A. Di Pietro. *European Review for Medical and Pharmacological Sciences* **2019**; 23(16): 7163-7182. (IF: 3,784). doi: 10.26355/eurrev_201908_18763. ISSN: 2284-0729. PMID: 31486519. WOS:000484079700046. SCOPUS: 2-s2.0-85071484224.

81. The treatment of Kaposi’s sarcoma: present and future options, a review of the literature. M. Ceccarelli, A. Facciola, R. Taibi, **G.F. Pellicanò**, G. Nunnari, E. Venanzi Rullo. *European Review for Medical and Pharmacological Sciences* **2019**; 23 (17): 7488-7497. doi: 10.26355/eurrev_201909_18860. (IF: 3,784). PMID: 31539137. WOS:000488119300035. SCOPUS: 2-s2.0-85072191438.

80. Vaccines against HPV in people living with HIV: a review. F. D’Andrea, M. Ceccarelli, E. Venanzi Rullo, A. Facciola, A. Marino, B. Cacopardo, **G.F. Pellicanò**, G. Nunnari. *WCRJ* **2019**; 6: e1348. doi: 10.32113/wcrj_20197_1348. WOS:000475865600001. ISSN: 2372-3416.

79. Knowledge of sexually transmitted infections and risky behaviours: a survey among high school and university students. G. Visalli, B. Cosenza, F. Mazzù, M.P. Bertuccio, P. Spataro, **G.F. Pellicanò**, A. Di Pietro, I. Picerno, A. Facciola. *J PREV MED HYG* **2019**; 60: EB4-E92. Doi: 10.15167/2421-4248/jpmh2019.60.2.1079. ISSN: 1121-2233. SCOPUS: 2-s2.0-85068372358.

78. Anal cancer in people living with HIV: the importance of the screening and of early diagnosis. F. D’Aleo, M. Ceccarelli, E. Venanzi Rullo, A. Facciola, F. D’Andrea, C. Micali, M. Coco, M.R. Pinzone, E. Focà, F. Condorelli, I. Picerno, B. Cacopardo, G. Nunnari, **G.F. Pellicanò**. *WCRJ* **2019**; 6: e1319. doi: 10.32113/wcrj_20196_1319. WOS:000472659000001.

77. An evaluation of the burden of invasive Enterococcal infection in a large university hospital. A. Facciola, M. Ceccarelli, E. Venanzi Rullo, F. D’Aleo, I.A. Paolucci, F. D’Andrea, P. Momdello, M.R. Lo Presti, D. Marabto, **G.F. Pellicanò**. *INFECT DIS TROP MED* **2019**; 5:e523. Doi: 10.32113/idthm_20195_523. ISSN: 2379-4054

76. Hodgkin’s lymphoma in people living with HIV: epidemiology and clinical management. A. Facciola, E. Venanzi Rullo, M. Ceccarelli, F. D’Aleo, F. D’Andrea, G. Visalli, M.R. Pinzone, I. Picerno, B. Cacopardo, F. Condorelli, G. Madeddu, G. Nunnari, **G.F. Pellicanò**. *WCRJ* **2019**; 6: e1295. Doi: 10.32113/wcrj_20195_1295. ISSN: 2372-3416. WOS:000468793800001.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

75. *Lipid profile improvement in virologically suppressed HIV-infected patients switched to dolutegravir/abacavir/lamivudina: data from the SCOLTA project.* Bagella P., Squillace N. Ricci E., Gulminetti R., De Socio G.V., Taramasso L., **Pellicanò G.F.**, Menzaghi B., Celesia B.M., Dentone C., Orofino G.C., Bonfanti P., Madeddu G. *Infection and Drug Resistance*. **2019**;12; 1385-1391. (IF: 4,177). Doi: 10.2147/IDR.S203813. ISSN: 1178-6973. PMCID: PMC6536892. PMID: 31213857. SCOPUS: 2-s2.0-85066758598. WOS:000469366500003.

74. *Switching from Tenofovir disoproxil fumarate (TDF) Tenofovir alafenamide (TAF) and Cholesterol increase: impact on cardiovascular assessment.* N. Squillace, E. Ricci, B. Menzaghi, G.M. Migliorino, G.V. De Socio, S. Passerini, C. Martinelli, M.S. Mameli, P. Maggi, K. Falasca, L. Cordier, B.M. Celesia, E. Salomoni, A. Di Biagio, **G.F. Pellicanò** and P. Bonfanti for the CISAI Study Group. *JHA* **2019**; Meeting Abstract: P218, Volume: 21 Special Issue: SI; Supplement: 8; Published: OCT 2018. 4(1): 12-16. DOI: 10.19198/JHA31469. ISSN: 2499-5819. WOS:000448482200255. SCOPUS: 2-s2.0-85055614577.

73. *Outbreak of Brucella melitensis infection in Eastern Sicily: risk factors, clinical characteristics and complication rate.* B.A.V. Cama, M. Ceccarelli, E. Venanzi Rullo, F. Ferraiolo, I. A. Paolucci, D. Maranto, P. Mondello, M.R. Lo Presti Costantino, F. Marano, G. D'Andrea, V. Di Marco, G. Puglisi, M. Valenzise, G. D'Angelo, L. Mondello, G. Strano, F. Condorelli, D. Spicola, G. Nunnari, **G. F. Pellicanò**. *New Microbiol.* 2019 42(1); 43-48. JAN **2019**. PMID: 30957869. ISSN: 1121-7138. Article identifier: 496N058. SCOPUS: 2-s2.0-850064518458. WOS:000463828400005.

72. *The role of the hospital environment in the healthcare-associated infections: a general review of the literature.* A. Facciola, **G.F. Pellicanò**, G. Visalli, I.A. Paolucci, M. Ceccarelli, F. D'Aleo, A. Di Pietro, R. Squeri, G. Nunnari. V. La Fauci. *European Review for Medical and Pharmacological Sciences*. **2019**; 23 (3): 1266-1278. Doi: 10.26355/eurrev_201902_17020. FEBR 2019. (IF: 3,784). PMID: 30779096. WOS:000459178100045. SCOPUS: 2-s2.0-85061853785.

71. *Breast Cancer in Women Living with HIV.* D'Andrea F., Ceccarelli M., Facciola A., G. Nunnari, **G.F. Pellicanò**, E. Venanzi Rullo. *European Review for Medical and Pharmacological Sciences*. 2019; 23 (3): 1158-1164. FEBR **2019**. (IF: 3,784). Doi: 10.26355/eurrev_201902_17007. PMID: 30779085. WOS:000459178100034. SCOPUS: 2-s2.0-85061859840.

70. *Investigational Drugs in HIV: Pros and Cons of entry and fusion inhibitors (review).* E. Venanzi Rullo, M. Ceccarelli, F. Condorelli, A. Facciola, G. Visalli, F. D'Aleo, I. Paolucci, B. Cacopardo, M. R. Pinzone, M. Di Rosa, G. Nunnari, **G.F. Pellicanò**. *Molecular Medicine Reports*, **2019**, 19(3), 1987-1995. Published online: jan 10 2019; MAR 2019. doi: 10.3892/mmr.2019.9840. ISSN: 1791-3004. PMID: 30628713. WOS:000459710100067. SCOPUS: 2-s2.0-85060580582.

69. *Cervical cancer in women living with hiv: a review of the literature.* F. D'Andrea, **G.F. Pellicanò**, E. Venanzi Rullo, F. D'Aleo, A. Facciola, C. Micali, M. Coco, G. Visalli, I. Picerno, F. Condorelli, M.R. Pinzone, B. Cacopardo, G. Nunnari, M. Ceccarelli. *Word Cancer Research Journal – WCRJ* **2019**; 6: e1224. ISSN: 2372-3416. Doi: 10.32113/wcrj_20193_1224. **Flavia D'Andrea e Giovanni Francesco Pellicanò equally contributed to this work.** WOS:000467867800001.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

68. *Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV* subjects on cART: A potential marker of kidney disease.* M.R. Pinzone, M. Ceccarelli, E. Venanzi Rullo, M. Maresca, R. Bruno, F. Condorelli, M. Di Rosa, G. Madeddu, E. Focà, A. Calcagno, B.M. Celesia, B. Cacopardo, G. Nunnari, **G.F. Pellicanò**. Biomedical Reports (IF:), Published online on: Jan 7 **2019**. Vol. 10(2). Pagg. 140-144, **2019** Feb. doi: 10.3892/br.2019.1183. ISSN: 2049-9442. PMID: 30675354. PMCID: PMC6341407. WOS:000460799200010. SCOPUS: 2-s2.0-85059676792.

67. *Carbon nanotubes and central nervous system: environmental risks, toxicological aspects and future perspectives.* A. Facciola; G. Visalli; S. La Maestra; M. Ceccarelli; F. D'Aleo; G. Nunnari; **G. F. Pellicanò**; A. Di Pietro. Environmental Toxicology and Pharmacology 65; 23-30. Doi: 10.1016/j.etap.2018.11.006. JAN **2019**. (IF: 5,785). ISSN 1382-6689. eISSN: 1872-7077. PMID: 30500734. WOS:000457814500005. SCOPUS: 2-s2.0-85057193134.

66. *Predictors weight gain in patients treated with Dolutegravir.* L. Taramasso, P. Bonfanti, E. Ricci, N. Squillace, B. Menzaghi, G. Madeddu, G.V. De Socio, G. Orofino, B.M. Celesia, **G.F. Pellicanò**, R. Gulminetti, C. Martinelli, F. Vichi, G. Cenderello, P. Maggi, G. Angioni, S. Rusconi, G. Parruti, A. Bandera, A. Gori, A. Di Biagio. For the CISA Group. EACS 2019 – Basilea (CH) 6-9 novembre **2019** - SESSIONE POSTER- PE32/3. HIV MEDICINE Vol. 20 (9); p. 274-275. ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300626.

65. *Switching from Tenofovir disoproxil fumarate (TDF) to Tenofovir alafenamide (TAF) lowers alanine transaminase (ALT) and aspartate transaminase (AST) in patients with infection with or without viral hepatitis co-infection.* N. Squillace, E. Ricci, B. Menzaghi, G. Migliorino, G.V. De Socio, S. Rusconi, C. Martinelli, G. Madeddu, P. Maggi, K. Falasca, L. Cordier, B.M. Celesia, F. Vichi, A. Di Biagio, **G.F. Pellicanò**, G. Orofino, P. Bonfanti, for the CISA Group. EACS **2019** – Basilea (CH) 6-9 novembre 2019 - SESSIONE POSTER – PE32/5. HIV MEDICINE Vol. 20 (9); p. 275-276. ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300628.

64. *HIV-associated psoriasis: epidemiology, pathogenesis and management.* M. Ceccarelli, E. Venanzi Rullo, M. Vaccaro, A. Facciola, F. D'Aleo, I.A. Paolucci, S.P. Cannavò, B. Cacopardo, M.R. Pinzone, **G.F. Pellicanò**, F. Condorelli, G. Nunnari, C. Guarnieri. Dermatologic Therapy. 2019 Vol. 32 (6), 27 december 2018:e12806. 1-21. Published: MAR-APR **2019**. (IF: 3,858). Doi: 10.1111/dht.12806. eISSN: 1529-8019. ISSN: 1396-0296. PMID: 30588732. WOS:000462941000002. SCOPUS: 2-s2.0-85059585372.

63. *Epidemiologia delle farmacoresistenze di HIV nella Regione Sicilia.* C. Micali, E. Venanzi Rullo, M. Ceccarelli, F. D'Andrea, M.R. Lo Presti Costantino, A. Facciola, G. Visalli, I. Picerno, L. Mondello, L. Guarneri, G. Scifo, C. Iacobello, A. Montineri, B. Cacopardo, A. Cascio, S. Amato, G. Foti, E.M. Farinella, L. Panella, A. Davi, V. Catania, G. Nunnari, **G.F. Pellicanò**. Le Infezioni in Medicina. The Official Journal of the Italian Society of Infectious and Tropical Disease. Abstarct book del XVII Congresso Nazionale SIMIT. Torino 2-5 dicembre **2018**. P067. P. 231-2.

62. *Pseudomonas aeruginosa detection in South Italy: an epidemiological survey.* F. D'Andrea, I.A. Paolucci, M. Ceccarelli, F. D'Aleo, D. Iannello, A. Facciola, G. Mancuso, F. Venanzi Rullo, **G.F. Pellicanò**. Infect. Dis. Trop. Med. **2018**; 4 (4): e507. ISSN: 2379-4054.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

61. *Epidemiology of Klebsiella pneumoniae MDR during the years 2015-2017 in "G. Martino" University Hospital of Messina: preliminary data.* F. D'Aleo, E. Venanzi Rullo, I.A. Paolucci, B. Cacopardo, A. Facciola, F. Condorelli, M. Ceccarelli, P. Mondello, **G.F. Pellicanò**. Infect. Dis. Trop. Med. **2018**; 4 (3): e488. ISSN: 2379-4054.

60. *MRSA detection in South Italy: an epidemiological survey to evaluate the burden of this important public health issue.* A. Facciola, M. Ceccarelli, I.A. Paolucci, F. D'Aleo, B. Cacopardo, F. Condorelli, E. Venanzi Rullo, M.R. Lo Presti, Costantino, **G.F. Pellicanò**. Infect. Dis. Trop. Med. **2018**; 4 (3): e486. ISSN: 2379-4054.

59. *Nosocomial Citrobacter koseri urosepsis in an 87-year-old woman: a case report.* B.A.V. Cama, E. Venanzi Rullo, F. Condorelli, B. Cacopardo, F. D'Aleo, A. Facciola, **G.F. Pellicanò**, M. Ceccarelli. Infect. Dis. Trop. Med. **2018**; 4 (3): e484. ISSN: 2379-4054.

58. *Current fast methods for the identification of carbapenemase enzymes in clinical laboratory.* F. D'Aleo, M. Ceccarelli, A. Facciola, E. Venanzi Rullo, I.A. Paolucci, M.R. Lo Presti Costantino, P. Fazi, M. Conte, **G.F. Pellicanò**. Infect. Dis. Trop. Med. **2018**; 4 (2): e470. ISSN: 2379-4054.

57. *Expression of the OAS gene family is highly modulated in subjects affected by juvenile dermatomyositis, resembling an immune response to a dsRNA virus infection.* G. Musumeci, P. Castrogiovanni, I. Barbagallo, D. Tibullo, C. Sanfilippo, G. Nunnari, **G.F. Pellicanò**, P. Pavone, R. Caltabiano, R. Di Marco, R. Imbesi, M. Di Rosa. International Journal of Molecular Sciences – Int. J. Mol. Sci. **2018** Sep 17;19(9), (IF: 6,208). pii: E2786; doi:10.3390/ijms19092786. PMID: 30227596. PMCID: PMC6163680. WOS:000449988100322. SCOPUS: 2-s2.0-85053661864.

56. *Prostate cancer in HIV-positive patients: a review of the literature.* A. Facciola, M. Ceccarelli, E. Venanzi Rullo, F. D'Aleo, F. Condorelli, G. Visalli, B. Cacopardo, M.R. Pinzone, M. Di Rosa, G. Nunnari, **G.F. Pellicanò**. Word Cancer Research Journal – WCRJ **2018**; 5(3): e1136. WOS:000445154000011.

55. *Cancer screening in HIV-infected patients: early diagnosis in A high-risk population.* F. D'Andrea, M. Ceccarelli, E. Venanzi Rullo, A. Facciola, F. D'Aleo, B. Cacopardo, C. Iacobello, A. Costa, G. Altavilla, **G.F. Pellicanò**, G. Nunnari. Word Cancer Research Journal – WCRJ **2018**; 5(3): e1130. WOS:000445154000008. SCOPUS: 2-s2.0-85044080748. doi: 10.32113/wcrj_20189_1130.

54. *Hiv and colorectal cancer. New insights and review of the literature.* F. D'Aleo, E. Venanzi Rullo, M. Ceccarelli, A. Facciola, F. Condorelli, M.r. Pinzone, B. Cacopardo, M. Di Rosa, G. Nunnari. **G.F. Pellicanò**. Word Cancer Research Journal – WCRJ **2018**; 5(3): e1122. WOS:000445154000004.

53. *La terza età nella terapia antiretrovirale di combinazione. The third age of combination antiretroviral therapy.* A. Facciola, F. D'Aleo, M. Ceccarelli, **G.F. Pellicanò**. JHA **2018**; 3(2): 40-42. DOI: 10.19198/JHA31449. ISSN: 2499-5819.

52. *Bacteremic meningitis due to Pasteurella multocida resistant to first antibiotic therapy.* D. Larnè, M. Ceccarelli, F. Condorelli, E. Venanzi Rullo, G. Nunnari, **G.F. Pellicanò**. Infectious Disease Reports 2018; Sep

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

5;10(2):7632; 26-27. Doi: 10.4081/idr.2018.7632. eCollection **2018** Sep 5. (IF: PMID: 30283616. PMCID: PMC151349. WOS:000450508400001. SCOPUS: 2-s2.0-85052839719.

51. *Unusual Signs and Symptoms in HIV-Positive Patients Coinfected with Leishmania spp: The Importance of Neglected Tropical Disease in Differential Diagnosis.* Ceccarelli M., Venanzi Rullo E., Condorelli F., Vitale F., Di Marco V., Nunnari G., **Pellicanò G.F.** Macedonian Journal of Medical Sciences. 25 Aprile **2018**; 6(5):843-847. doi: 10.3889/oamjms.2018.186. eCollection 2018 may 20. eISSN: 1857-9655. PMCID: PMC: 5985878. SCOPUS: 2-s2.0-85047424471.

50. *Serum interleukin-6 levels are increase in HIV.infected patients that develop autoimmune disease during long-term follow-up.* Trovato M., Ruggeri R.M., Sciacchitano S., Vicchio T.M., Picerno I., **Pellicanò G.**, Valenti A., Visalli G. Immunobiology. 2018 Mar; 223(3):264-268. doi: 10.1016/j.imbio.2017.10.039. Epub 2017 – Published: MAR **2018**. Oct 16. PMID: 29055566. WOS:000429397000002. SCOPUS: 2-s2.0-85031778465.

49. *Editorial – Improving acces and adherence to screening tests for cancers: a new, though old, challenge in the HIV epidemic.* Ceccarelli M., Condorelli F., Venanzi Rullo E., **Pellicanò G.F.** Word Cancer Research Journal **2018**; 5(1): e1036. ISSN: 2372-3416. WOS:000428464500006.

48. *Acute pericarditis during early-diagnosed Brucellosis: a case report.* Ceccarelli M., Venanzi Rullo E., Cama B.A.V., **Pellicanò G.F.** Infect. Dis. Trop. Med. **2018**; 4 (1): e443. ISSN: 2379-4054.

47. *Body fat changes in HIV patients on highly active antiretroviral therapy (HAART): a longitudinal DEXA study.* Nuvoli S., Caruana G., Babuderi S., Solinas P., **Pellicanò G.**, Piras B., Fiore V., Bagella P., Calia G.M., Yue M., Spanu A., Madeddu G. European Review for Medicinal and Pharmacological Sciences, **2018** Mar;22(6); 1852-1859. Doi: 10.26355/eurev_201803_14606. (IF: 3,784). PMID: 29630136. WOS:000429678700048. SCOPUS: 2-s2.0-85045879381.

46. *New and old assumptions on lung cancer in people living with HIV.* D'Aleo F., Cama B.A.V., Paolucci I., Venanzi Rullo E., Condorelli F., Facciola A., Di Francia R., Savasta A., Pinzone M.R., Picerno I., Visalli G., Nunnari G. **Pellicanò G.F.**, Ceccarelli M. Word Cancer Research Journal **2018**; 5(1): e1036. WOS:000428464500008.

45. *Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HV: a systematic review.* Ceccarelli M., Venanzi Rullo E., Facciola A., Madeddu G., Cacopardo B., Taibi R., D'Aleo F., Pinzone M.R., Picerno I., Di Rosa M., Visalli G., Condorelli F., Nunnari G., **Pellicanò G.F.** Oncotarget, 2018 Mar 30; 9(24): 17171-17180. doi: 10.18632/oncotarget.24660. eCollection **2018** Mar 30. Review. PMID: 29682214. PMCID: PMC5908315. SCOPUS: 2-s2.0-85044792151. ISSN: 1949-2553.

44. *HPV and urinary bladder carcinoma: a review of the literature.* Visalli G., Facciola A., D'Aleo F., Condorelli F., Picerno I., Nunnari G., **Pellicanò G. F.**, Ceccarelli M., Venanzi Rullo E. Word Cancer Research Journal **2018**; 5(1): e1038. WOS:000428464500009.

43. *Switching from Tenofovir disoproxil fumarate (TDF) to Tenofovir alafenamide (TAF) and hepatic safety: a new paradigm?* N. Squillace, E. Ricci, B. Menzaghi, G. Migliorino, G.V. De Socio, S. Passerini, C. Martinelli, G. Madeddu, P. Maggi, K. Falasca, L. Cordier, B.M. Celesia, F. Vichi, A. Di Biagio, **G.F. Pellicanò** and P. Bonfanti, for

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

the CISAI Study Group. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P218. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8); (IF: 6,707). ISSN: 1758-2652. WOS:000448482200255. Doi: 10.1002/jia2.25187. SCOPUS: 2-s2.0-85055614577.

42. *Hepatitis C-related hepatocellular carcinoma: diagnostic and therapeutic management in HIV-patients*. F. D'Aleo; M. Ceccarelli; E. Venanzi Rullo; A. Facciola; M. Rosa²; M. R. Pinzone; F. Condorelli; G. Visalli, I. Picerno, M. Berretta; **G. F. Pellicanò**; G. Nunnari. European Review for Medical and Pharmacological Sciences **2017** Dec; 21(24): 5859-5867. doi: 10.26355/eurrev_201712_14035. (IF: 3,784). PMID: 29272025. WOS:000423238900044. SCOPUS: 2-s2.0-85038845962.

41. *Kaposi's sarcoma in HIV-infected patients in the era of new antiretrovirals*. A. Facciola, E. Venanzi Rullo, M. Ceccarelli, F. D'Aleo, M. Di Rosa, M.R. Pinzone, F. Condorelli, G. Visalli, I. Picerno, R. Fisichella, G. Nunnari, **G.F. Pellicanò**. European Review for Medical and Pharmacological Sciences **2017** Dec; 21(24): 5868-5879. doi: 10.26355/eurrev_201712_14036. (IF: 3,784). PMID: 29272026. WOS:000423238900045. SCOPUS: 2-s2.0-85039549073.

40. *High fecal calprotectin levels during lymph-nodal and abdominal tuberculosis*. D. Larnè, **G.F. Pellicanò**, E. Venanzi Rullo, M. Ceccarelli. Infect Dis Trop Med – Dicembre **2017**; 3 (4): e419. ISSN: 2379-4054.

39. *Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: data from surveillance color long term toxicity antiretrovirals/antivirale (SCOLTA) project*. Squillace N., Ricci E., Quirino T., Carenzi L., De Socio G.V., Orofino G., Martinelli C., Madeddu G., Rusconi S., Maggi P., Celesia B.M., Cordier L., Vichi F., Calza L., Falasca K., Di Biagio A., **Pellicanò G.**, Bonfanti P., for the CISAI Study Group. PLoS ONE. 2017 Jun 20;12(6):e0179254. (IF: 3,752). Doi: 10.1371/journal.pone.0179254. eCollection **2017**. PMID: 28632758. Pmcid: pmc5478131. Doi: 10.1371/journal.pone.0179254. SCOPUS: 2-s2.0-85021143329. WOS:000404046100014.

38. *Number and characteristics of new HIV diagnoses in the Calabria Region and in one nearby centre in Messina: a resurgent or still hidden epidemic in Southern Italy?* Postorino M.C., Luciani F., **Pellicanò G.**, Mangano C., Carpentieri M.S., Scerbo P., Priamo A., Berardelli G., Marino R., Vallone A., Carioti J., Serrao N., Pisani V., Costa C., Cesario F., Terremoto A., Foti G., Cosco L., Corigliano D., Mazzitelli M., Strazzulla A., Nunnari G., Torti C. Infect Dis, Trop Med **2016**; 2 (2): e297. ISSN: 2379-4054.

37. *Kaposi's sarcoma in HIV-infected patients: a review of the literature*. L. La Ferla, M.R. Pinzone, **G.F. Pellicanò**, G. Nunnari. Infect Dis Trop Med **2016**; 2 (1): e239. ISSN: 2379-4054.

36. *Dolutegravir tolerability in clinical practice: results from the Surveillance Cohort Long-Term Toxicity Antiretrovirals/Antivirals (SCOLTA) Cohort*. Madeddu G., Ricci E., Gulminetti R., Bagella P., Squillace N., De Socio G., Menzaghi B., Orofino G., Molteni C., Rusconi S., Celesia B.M., Bellacosa C., Di Biagio A., **Pellicanò G.**, Martinelli C., Carenzi L., Valsecchi L., Calza L., Falasca K., Vichi F., Penco G., Bonfanti P. HIV DRUG THERAPY. October 23-26, **2016** Glasgow, UK. Doi: 10.7448/ias.19.8.21487. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. Vol. 19 (S7). (IF: 6,707). Meeting Abstract. ISSN: 1758-2652. WOS:000395394900267.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

35. *Self-reported sexual dysfunction in HIV-positive subjects: a cross-sectional study.* M.R. Pinzone, M. Gussio, F. Bellissimo, C. Coco, F. Bisicchia, **G. Pellicanò**, F. Palermo, M.T. Mughini, B. Cacopardo, G. Nunnari, B. M. Celesia. *Infect Dis Trop Med* **2015**; 1 (2): e1045. ISSN: 2379-4054.

34. *HIV infection and kidney disease: literature review.* M. Scarpino, M. Santoro, **G. Pellicanò**. *Infect Dis Trop Med* **2015**; 1 (4): e195. ISSN: 2379-4054.

33. *Four years data of raltegravir-based salvage therapy in HIV-1 infected, treatment-experienced patients: the SALIR-E Study.* A. Capetti, P. Meraviglia, S. Landonio, G. Sterrantino, A. Di Biagio, S. Lo Caputo, A. Ammassari, B. Menzaghi, G. V. De Socio, M. Franzetti, A. Soria, M. Meschiari, L. Sasset, **G. Pellicanò**, E. Mazzotta, M. Trezzi, B.M. Celesia, S. Melzi, L. Carenzi, E. Ricci, G. Rizzardini. *Int J Antimicrob Agents*. 2014 Feb;42(2):189-94. (IF: 15,441). Doi: 10.1016/j.ijantimicag.2013.10.013. Epub **2013** Nov 15. PMID: 24315315. WOS:000330189000016. SCOPUS: 2-s2.0-84893691010.

32. *Correspondence: Cytomegalovirus complicating inflammatory bowel disease: Useful remarks.* A. Cascio, C. Iaria, F. Ricciardi, **G. Pellicanò**, W. Fries. *Gastroenterology and Hepatology* Vol. 9. Issue 11, November **2013**, pag.: 756-757. ISSN: 15547914. PMCID: PMC3995202. SCOPUS: 2-s2.0-84892567058.

31. *High prevalence of undiagnosed anxiety symptoms among HIV-positive individuals on cART: a cross-sectional study.* Celesia BM, Nigro L, Pinzone MR, Coco C, La Rosa R, Bisicchia F, Mavilla S, Gussio M, **Pellicanò G**, Milioni V, Palermo F, Russo R, Mughini MT, Martellotta F, Tabi R, Cacopardo B, Nunnari G. *Eur Rev Med Pharmacol Sci*. **2013** Aug; 17(15): 2040-6. (IF: 3,784). PMID: 23884824. ISSN:1128-3602. WOS:000325204100007. SCOPUS: 2-s2.0-84884259149.

30. *Bone marrow biopsy findings in brucellosis patients with hematologic abnormalities: useful remarks.* A. Cascio, **G. Pellicanò**, L.M. Pernice, A. David, C. Iaria. *Chinese medical journal* **2013**; 126(5):1000. (IF: 6,133). DOI: 10.3760/cma.j.issn.0366-6999.20122718. WOS:000319783500047. SCOPUS: 2-s2.0-84875347809.

29. *96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience.* Amedeo Capetti, Simona Landonio, Paola Meraviglia, Antonio Di Biagio, Sergio Lo Caputo, Gaetana Sterrantino, Adriana Ammassari, Barbara Menzaghi, Marco Franzetti, Giuseppe Vittorio De Socio, **Giovanni Pellicano'**, Elena Mazzotta, Alessandro Soria, Marianna Meschiari, Michele Trezzi, Lolita Sasset, Benedetto Maurizio Celesia, Patrizia Zucchi, Sara Melzi, Elena Ricci, Giuliano Rizzardini. *PLOS ONE*; July **2012**/Volume 7(7)/e39222. (IF: 3,752). ISSN: 1932-6203. doi: 10.1371/journal.pone.0039222.t001. PMCID: 22808029 - PMC3394760. WOS:000306362400009. SCOPUS: 2-s2.0-84863850985.

28. *Bioenergetics of T Cell Activation and Death in HIV Type 1 Infection.* Visalli G., Bertuccio M.P., Currò M., **Pellicano' G.**, Sturniolo G., Carnevali A. Spataro P., Ientile R., Picerno I., Cavallari V., Piedimonte G. *AIDS Res Hum Retroviruses*. (IF: 1,723). **2012** Apr 3. 28(9): 910-918. PMID: 22050664. ISSN: 0889-2229; Online ISSN: 1931-8405. DOI:10.1089/aid.2011.0197. WOS:000308337300023. SCOPUS: 2-s2.0- 84865474810.

27. *Efficacy of 1998 vs 2006 first-line antiretroviral regimens for HIV infection: an ordinary clinics retrospective investigation.* Parruti G., Polilli E., De Socio G., Sozio F., Marconi P., Soddu V., D'Alessandro, M.,

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Celesia B. M., **Pellicanò G.**, Madeddu G., Vecchiet J., Di Masi F., Mazzotta E., Ursini T., Martinelli C., Vitiello P., Bonfanti P., Nigro L., Mura M. S. A., Antinori A., Ricci E., Manzoli L. *Journal of Antivirals and Antiretrovirals*, Vol. 4 (2), p. 32-37. eISSN 1948-5964. Aprile **2012**. ISSN: 1948-5964. DOI:10.4172/jaa.1000043. WOS:000272573600003. SCOPUS: 2-s2.0-84863557274.

26. *Is there a relation between myalgia and central nervous system symptoms in patients receiving Raltegravir? Results from the Scolta Project.* G. Madeddu, V. Soddu, E. Ricci, T. Quirino, B. Menzaghi, C. Bellacosa, C. Grosso, L. Carezzi, L. Cordier, M. Franzetti, F. Vichi, G. Penco, C. Martinelli, P. Maggi, A. Di Biagio, **G.F. Pellicanò**, L. Corsico, G.V.L. De Socio, E. Mazzotta, G. Parruti, M. Guastavigna, G.C. Orofino, M.S. Mura, P. Bonfanti. *Infection* (**2011**) 39 (S1):S29-S30. (IF: 7,455). ICAR Firenze 27-29 marzo 2011. Doi: 10.1007/s15010-011-0090-z. WOS:000288832500045.

25. *Analysis of efficacy and tolerability of raltegravir based regimens by background in salvage: a Multicentre Italian Experience.* S. Landonio, A. Capetti, P. Meraviglia, A. Di Biagio, S. Lo Caputo, G. Sterrantino, A. Ammassari, B. Menzaghi, M. Franzetti, G.V. de Socio, **G.F. Pellicanò**, E. Mazzotta, S. Melzi, P. Zucchi, G. Rizzardini. *Infection* (**2011**) 39 (S1):S65-S66. (IF: 7,455). ICAR Firenze 27-29 marzo 2011. WOS:000288832500130. SCOPUS: 2-s2.0-84893691010.

24. *Once-day (QD) vs. twice-daily (BID) nevirapina as simplification in PI-treated patients after 2 mos. Of BID induction.* Maserati R, Brandolini M, Cattelan A, Orani A, Sighinolfi L, Andreoni M, Uglietti A, Guaraldi G, Sotgiu G, Manconi PE, **G.F. Pellicanò** [.....], Angioni G, Francavilla E, Malena M, Manfrin V, Lazzarin A, Castagna A, Rusconi S, Mezzaroma I, Cerioli A, Scalzini A. *Current HIV Research*. 04/**2011**; 9(3-ISSN: 1570-162X):166-173. WOS:000299646400005. Scopus: 2-s2.0-79959321686.

23. *Nucleolin relocation associated top re-lethal alterations of T cell morphology: redefining death in HIV infection.* Visalli, Giuseppa; Bertuccio, Maria Paola; Chirico, Cristina; **Pellicano', Giovanni Francesco**; Spataro, Pasquale; Riccardo, Ientile; Isa, Picerno; Giuseppe, Piedimonte. DOI: 10.1186/1742-4690. pp. 22-22. In 16th International Symposium on HIV and Emerging Infectious Diseases. In RETROVIROLOGY **2010**; 7 (Suppl 1): P21-22. (IF: 3,768). Doi: 10.1186/1742-4690-7-s1-p22. PMCID: 1742-4690 - PMC3316102. WOS:000278329600069.

22. *Muscle symptoms and creatinine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study.* G. Madeddu, V. Soddu, E. Ricci, T. Quirino, B. Menzaghi, C. Bellacosa, C. Grosso, S. Melzi, I. Valsecchi. M. Franzetti, F. Vichi, G. Penco, A. Di Biagio, **G.F. Pellicanò**, L. Corsico, GVL De Socio, E. Mazzotta, G. Parruti, M. Guastavigna, G. Orofino, MS Mura, p. Bonfanti. *Journal of the international AIDS Society*. **2010** 13 (Suppl 4):P111. <http://www.jiassociety.org/content/13/S4/P111>. Doi: 10.1186/1758-2652-13-s4-9111. Pmcid: pmc3112886.

21. *Prevalence of HLA-B5701 and access to genetic test in Sicily. A multicenter study.* M.T. Mughini, F. Bisicchia, B.M. Cesia, **G.F. Pellicanò**, T. Prestileo, S. Galvagna, A. Ragusa, A. Franco, A. Iacono, F. Trifiletti, C. Colomba, F. Pulvirenti, A. Salvo, V. Portelli, R. Russo. *Infection –A Journal of Infectious Disease*. Vol. 38, Suppl 1. (IF: 7,455). ICAR Brescia 20-22 June **2010**. Doi: 10.1007/s15010-010-1001-4. WOS:000279007400097.

20. *Long-term follow-up of HIV-infected patients in salvage therapy with raltegravir plus optimized background regimens: a multicentre Italian experience.* S. Landonio, P. Meraviglia, A.F. Capetti, A. Di Biagio, S. Lo Caputo.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

G. Sterrantino, A. Ammassari, G. De Socio, **G. Pellicanò**, E. Mazzotta, P. Zucchi, G. Rizzardini. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 7-11 November 2010. J Int AIDS Soc. **2010**; 13(Suppl 4): P38. (IF: 6,707). Doi: 10.1186/1758-2652-13s4-p38. PMCID: PMC3113040.

19. Intracellular accumulation of cell cycle regulatory proteins and nucleolin re-localization are associated with pre-lethal ultrastructural lesions in circulating T lymphocytes – The HIV-induced cell cycle dysregulation revisited. G. Visalli, M. Paiardini, C. Chirico, B. Cervasi, M. Currò, N. Ferlazzo, M.P. Bertuccio, A. Favaloro, **G. Pellicanò**, P. Spataro, R. Ientile, I. Picerno, G. Piedimonte. Cell Cycle 9(11), 2130-2140; June 1, **2010**. (IF: 5,173). DOI: 10.4161/cc.9.11.11754. ISSN 1538-4101. PMCID: 20505329. WOS:000279148400025. SCOPUS: 2-s2.0-77953552203.

18. Proteasome inactivation and cell vacuolization during the activation induced death of T cell from HIV+ patients. Visalli G., Bertuccio M.P., **Pellicanò G.**, Sturniolo G., Spataro P., Piedimonte G., Picerno I. AIDS 2010. XVIII International AIDS Conference. 18-23 July **2010**. Vienna.

17. Anxiety disorders and adherence to HAART. Celesia B.M., Coco C.A., Bisicchia F., **Pellicanò G.**, Nunnari G., Mughini M.T., Palermo F., Russo R. AIDS 2010. XVIII International AIDS Conference. 18-23 July **2010**. Vienna.

*16. Prevalence of HLA-B*5701 and access to genetic test in Sicily. A multicenter study.* Mughini T., Celesia B.M., Bisicchia F., Russo R., **Pellicanò G.** Infection 38 (Suppl 1):57. June 2010. ICAR **2010**, Brescia 20-22 June 2010. Doi: 10.1007/s15010-010-1001-4. ISSN: 0300-8126. WOS:000279007400097.

15. Sexual dysfunction in HIV+ subjects in eastern Sicily. Mughini T., Celesia B.M., Bisicchia F., Russo R., **Pellicanò G.** Infection 38 (Suppl 1):78. June 2010. (IF: 7,455). ICAR 2010, Brescia 20-22 June **2010**. Doi: 10.1007/s15010-010-1001-4. DOI: 10.1186/1758-2652-13-S4-P109. PMCID: PMC3112883. ISSN: 0300-8126. WOS:000279007400140.

14. Nucleolin relocalization associated with pre-lethal alterations of T cell morphology: redefining cell death in HIV infection. Visalli G., Bertuccio M.P., Chirico C., **Pellicanò G.**, Spataro p., Ientile R., Picerno I., Piedimonte G. 16th International Symposium on HIV and Emerging Infectious Disease. Marseille, France. 24-26 March **2010**. Retrovirology 2010, 7(Suppl 1): P22. WOS:000278329600069.

13. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study. Giuntini R., Martinelli C., Ricci E., Vichi F., Gianelli E., Madeddu G., Abeli C., Palvarini L., Penco G., Marconi P., Grosso C., **Pellicanò G.**, Bonfanti P., Quirino T. HIV Med. 2010 Jan; 11(1): 40-5. Doi: 10.1111/j.1468-1293.2009.00740.x. Epub **2009** Aug 3. SCOPUS: 2-s2.0-72449169534. WOS: 000272573600003. ISSN: 1464-2662. PMID: 19686438.

12. 48 Week efficacy of first line antiretroviral treatments for hiv infection in 1998 and 2006: preliminary results of a multicentric investigation. Sozio F., Soddu V., De Socio G., Marconi P., D'Alessandro M., Madeddu G., Bonfanti P., Mazzotta E., Vecchiet J., Celesia M., **Pellicanò G.**, Di Masi F., Martinelli C., Vitiello P., Nigro L., Manzoli L., Parruti G. Infection – A Journal of Infectious Disease; ICAR May 24-26, **2009**; 37 (Supp. II): 19. (IF: 7,455). ISSN 0300-8126 (Print) 1439-0973 (Online). WOS:000268247200002.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

11. *Long-term efficacy of boosted and unboosted atazanavir-containing regimens: results from the SCOLTA Project.* Quirino T., Ricci E., Giuntini R., Martinelli C., Vichi F., Gianelli E., Madeddu G., Menzaghi B., De Socio G., Orofino G., Palvarini L., Penco G., Rosella E., Marconi P., Carradori S., Grosso C., **Pellicanò G.** and Bonfanti P. *Journal of the International AIDS Society* **2008**, II(Suppl 1):P74. Doi: 10.1186/1758-2652-11-S1-P74.
10. *Il tenofovir nella terapia antiretrovirale: osservazioni sulla possibile nefrotossicità del farmaco.* **Pellicanò G.**, Sturniolo G., Santoro M., Lo Presti M.R. *Dama. N.* 1-gennaio **2007**.
9. *Treatment of chronic brucellosis with ciprofloxacin. Personal experience.* Struniolo G., Ricciardi F., Costantino G., **Pellicanò G.**, Bertuccio O., La Rosa F. *Minerva Medica* **1993** Apr; 84(4):187-90 PMID: 8506057. ISSN: 0026-4806. SCOPUS: 2-s2.0-0027216068.
8. *Ruolo dell'alcool nel determinismo di episodi di fibrillazione atriale.* **Pellicanò G.F.**, Lombardo S., Trimarchi S., Orlando F., Niosi G., Purello D'Ambrosio F. pp.1-4. In *RASSEGNA MEDICA*, **1988** - ISSN:0394-7920 vol. 4.
7. *Encefalopatia latente in corso di cirrosi alcolica.* **Pellicanò G.F.**, Tigano V., Niosi G., Trimarchi S., Orlando F., Lombardo G., Purello d'Ambrosio F. pp.1-5. In *RASSEGNA MEDICA*, **1987** - ISSN:0394-7920 vol. 12.
6. *La ragade anale: aspetti etiopatologici e implicazioni terapeutiche.* **Pellicanò G.F.**, Angiò L.G., Giachino E., Pettinato M., De Marco A. Panunzio p. Niosi G. pp.1-38. In *RASSEGNA MEDICA*, **1987** - ISSN:0394-7920 vol. 12-
5. *Contributo epidemiologico e considerazioni sulla scarlattina oggi.* **Pellicanò G.F.**, Caruso R., Parisi A., Parisi S. pp.73-77. In *RIVISTA DI PATOLOGIA E CLINICA*, **1987** - ISSN:0035-6417 vol. 42.
4. *Correlazioni istocitopatologiche ed amplificazione dell'antocorpo monoclonale Ca 19/9 nella diagnosi delle neoplasie epiteliali dell'ampolla di Vater.* **Pellicanò G.F.**, Chemicata S., Caruso R., Infrerra C. pp.427-436. In *PATHOLOGICA*, 1987 - ISSN:0031-2983 vol. 79.
3. *Nostro contributo nel trattamento ambulatoriale delle emorroidi mediante legatura elastica. Risultati preliminari.* **Pellicanò G.F.**, Angiò L.G., Giachino E., Pettinato M., Panunzio P., De Marco A., Lombardo G. pp.27-50. In *RASSEGNA MEDICA*, 1987 - ISSN:0394-7920 vol. 1.
2. *Correlation of histopathology and application of CA 19/9 monoclonal antibodies in the diagnosis of Vater's ampulla epithelial neoplasms.* S. Chemicata, R. Caruso, **G. Pellicanò**, C. Infrerra. *Pathologica*, **1987** Jul-Aug; 79 (1062): 427-36. SCOPUS: 2-s2.0-0023375755.
1. *Lesioni iperplastiche e adenomatoze dello stomaco: valutazioni morfoepidemiologiche ed istogenetiche.* **Pellicanò G.F.**, Parisi S., Caruso R., Parisi A. pp.155-169. In *RIVISTA DI ANATOMIA PATOLOGICA E DI ONCOLOGIA*, **1987** - ISSN:0048-8364 vol. 46.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

ARTICOLI IN CUI L'AUTORE FA PARTE DEL "COLLABORATION GROUP"

64. *Long-term outcome of dolutegravir-containing regimens according to sex: data from the ICONA Study.* A. d'Arminio Monforte, A. Tavelli, M. Sala, A. Mondì, S. Rusconi, S. Antinori, M. Puoti, B.M. Celesia, L. Taramasso, A. Saracino, A. Antinori, A. Cozzi-Lepri on behalf of ICONA Foundation Study Group: **G.F. Pellicanò**, G. Nunnari. *Journal of Antimicrobial Chemotherapy*, **2023 Feb 13**:dkad026. doi: 10.1093/jac/dkad026. PMIND: 36775983. WOS:000929524000001.

63. *Real world efficacy of dolutegravir plus lamivudine in PLWH with undetectable viral load after previous failures.* Roberta Gagliardini, Patrizia Lorenzini, Alessandro Cozzi-Lepri, Alessandro Tavelli, Vanni Borghi, Laura Galli, Gianmarco Tagliaferri, Franco Maggiolo, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Andrea Antinori, for the Icona Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. *J Global Antimicrob Resist*. **2022 nov 16**;S2213-7165(22)00256-9. Doi: 10.1016/j.jgar.2022.11.010. PMID: 36402369.

62. *Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex.* A. Cingolani, A. Tavelli, G. V. Calvino, F. Maggiolo, E. Girardi, A. Cozzi-Lepri, A. Perziano, P. Meli, A. Camposeragna, S. Mattioli, D. Calzavara, R. Gagliardini, S. Nozza, A. Antinori, A. d'Arminio Monforte & for ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. *AIDS Care (IF: 1,887)*. **2022 May 17, 1-11**, PMID: 35579404. doi.org/10.1080/09540121.2022.2074960. ISSN: 0954-0121. eISSN: 1360-0451; WOS:000796912700001. SCOPUS: 2-s2.0-85131050479.

61. *Reversibility of Central Nervous System Adverse Events in Course of Art.* L. Taramasso, G. Orofino, E. Ricci, B. Menzaghi, G.V. De Socio, N. Squillace, G. Madeddu, F. Vichi, B.M. Celesia, C. Molteni, F. Conti, F. Del Puente, E. Sarchi, G. Angioni, A. Cascio, C. Grosso, G. Parruti, A. Di Biagio, P. Bonfanti, on behalf of CISA Study Group: G. Nunnari, **G.F. Pellicanò**. *Viruses* **2022**, 14, 12028-1040. Doi: 10-3390/v1451028. PMID: 35632768. PMCID: PMC9147522. WOS:000801254300001. SCOPUS: 2-s2.0-85130521275.

60. *Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy.* Cingolani A., Tavelli A., Maggiolo F., Perziano A., Saracino A., Vichi F., Cernuschi M., Guaraldi G., Quiros-Roldan E., Castagna A., Antinori A., A d'Arminio Monforte, Icona Foundation Study Group: **G.F. Pellicanò**, G. Nunnari. *J. Clin. Med.* **2022**, 11(2), 471-482. Doi: 10.3390/jcm11020471. ISSN: 2077-0383. PMID: 35054165. PMCID: PMC8781185. SCOPUS: 2-s2.0-85122888500. WOS:000757118300001.

59. *Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.* Bansi-Matharu L., Philips A., Opera C., Grabmeier-Pfistershammer K., Gunthard H.F., De Wit S., Guaraldi G., Vehreschild JJ., Wit F., Law M., Wasmuth J.C., Chkhartishvili N., d'Arminio Monforte A., Fontas E., Vesterbacka J., Miro JM., Castagna A., Stephan C., Llibre JM., Neesgaard B., Greenberg L., Smith C., Kirk O., Duvivier C., Dragovic G., Lundgren J., Dedes N., Knudsen A., Gallant J., Vannappagari V., Peters L., Elbrit D., Sarcletti M., Braun DL., Necsoi C., Mussini C., Bolokadze N., Hoy J., Mocroft A., Ryom L. – G. Nunnari, **G.F. Pellicanò**. *Lancet HIV*. **2021 Nov**;8(11);e711-e722. Doi: 10.1016/S2352-3018(21)00163-6. Epub 2021 Sep 20. PMID: 34555326. WOS:000719959300011. SCOPUS: 2-s2.0-85121944522.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

58. *Metabolic syndrome and body weight in people living with HIV infection: analysis of differences in three different cohort studies over a decade.* L. Taramasso, P. Bonfanti, E. Ricci, P. Maggi, G. Orofino, N. Squillace, B. Menzaghi, G. Madeddu, C. Molteni, M. Guastavigna, D. Francisci, A. Di Biagio, G. V. De Socio for the CISAI study group: G. Nunnari, **G.F. Pellicanò**. *HIV Medicine*. **2022**;00;1-10. Doi: 10.1111/hiv.13165. PMID: 34473897. ISSN: 1464-2662. eISSN: 1468-1293. WOS:000693916300001. SCOPUS: 2-s2.0-85114299131.

57. *Decrease in incidence rate of Hospitalizations due to AIDS-Defining conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy.* S. Nozza, L. Timelli, A. Saracino, N. Gianotti, C. Lazzeretti, A. Tavelli, M. Puoti, S. Lo Caputo, A. Antinori, A. d'Arminio Monforte, C. Mussini, E. Girardi and on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. *Journal of Clinical Medicine – MDPI*. **2021**, 10, 3391. (IF: 4,964). Doi: 10.3390/jcm10153391. PMID: 34362172. eISSN: 2077-0383. WOS:000682028500001. SCOPUS: 2-2.0-85114074357.

56. *Impact of HCV eradication on lipid metabolism in HIV/HCV coinfecting patients: data from ICONA and HepalICONA Foundation Cohort Study.* M. Spaziant, G. Taliani, G. Marchetti, A. Tavelli, M. Lichtner, A. Cingolani, S. Cicalini, E. Biliotti, E. Girardi, A. Antinori, M. Puoti, A. d'Arminio Monforte, A. Cozzi-Lepri, ICONA Foundation Study Group – G. Nunnari, **G.F. Pellicanò**. *Viruses* **2021**,13,1402. Doi: 10.3390/v13071402. 1999-4915. (IF: 5,818). E199971. <https://www.mdpi.com/journal/viruses>. PMID: 34372608. WOS: 000677018900001. SCOPUS: 2-s2.0-85111596941.

55. *Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.* R. Gagliardini, N. Gianotti, F. Maggiolo, A. Cozzi-Lepri, A. Antinori, S. Nozza, G. Lapadula, A. De Luca, C. Mussini, A. Gori, A. Saracino, M. Andreoni, A. D'Arminio Monforte, ICONA Foundation Study Group – G. Nunnari, **G.F. Pellicanò**. *International Journal of Antimicrobial Agents*. 19 July **2021**. (IF: 15,441). Doi: 10-1016/ijantimicag.2021.106406. PMID: 34293454. WOS:000415294600003. SCOPUS: 2-s2.0-85113811727.

54. *Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV.* E. Merlini, A. Cozzi-Lepri, A. Castagna, A. Costantini, S. Lo Caputo, S. Carrara, E. Quiros Roldan, M.A. Ursitti, A. Antinori, A. d'Arminio Monforte, G. Marchetti; **G.F. Pellicanò**, G. Nunnari. *BMC Infectious Diseases* **2021** Jun 24; 21(1):557-568. (IF: 3,667). Doi.: 10.1186/s12879-021-06330-1. PMID: 34167481. SCOPUS: 2-s2.0-85107780736. WOS:000668607300004.

53. *Does syphilis increase the risk of HIV-RNA elevation >200 copies/mL in HIV positive patients under effective antiretroviral treatment? Data from the ICONA cohort.* A. Giacomelli, A. Cozzi-Lepri, A. Cingolani, A. Tavelli, V. Mazzotta, D. Tesoro, M. Bassetti, A. Castagna, A. Di Biagiom M. Lichter, A. d'Arminio Monforte, S. Rusconi, ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. *J Acquir Immune Defc Syndr*. **2021** Jun 15. (IF: 3,771). PMID: 34138773. Doi: 10.1097/QAI.0000000000002749. WOS:000711669200006. SCOPUS: 2-s2.0-85118228461.

52. *Determinants of loss to care and risk of clinical progression in PLWH who are re-engaged in care after a temporary loss.* C. Mussini, P. Lorenzini, A. Cozzi-Lepri, A. Mammone, G. Guaraldi, G. Marchetti, M. Lichtner, G. Lapadula, S. Lo Caputo, A. Antinori, A. d'Arminio Monforte, E. Girardi, ICONA Foundation Study Group: G.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Nunnari, **G.F. Pellicanò**. SCIENTIFIC REPORT. **2021** May 5. 11(1) 9632. (IF: 4,996). Doi: 10.1038/s41598-021-88367-5. PMID: 33953250. ISSN: 2045-2322. WOS:000656459200013. SCOPUS: 2-s-0-85105330973.

51. *The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfectd patients: data from the ICONA Foundation Cohort*. A. Bandera, P. Lorenzini, L. Taramasso, A. Cozzi-Lepri, G. Lapadula, C. Mussini, A. Saracino, F. Ceccherini-Silberstein, M- Puoti, E. Quiros-Roldan, F. Montagnani, A. Antinori, A. d'Arminio Monforte, A. Gori, for the Iona Foundation Cohort, G. Nunnari, **G.F. Pellicanò**. Journal of Viral Hepatitis (JVH). 18 february **2021**;00:1-8. (IF: 3,517). Doi: 10.1111/jvh.13488. PMID: 33600068. ISSN: 1365-2893. NLM Unique: 9435672. SCOPUS: 2-s2.0-85102316956. WOS:000627504500001.

50. *Time spent with viral load≤200 copies/mL in a cohort of people with HIV seen for care in Italy during the U=U prevention campaign era*. G. Madeddu, A. De Vito, A. Cozzi-Lepri, A. Cingolani, F. Maggiolo, C.F. Perno, R. Gagliardini, G. Marchetti, A. Saracino, A. D'Arminio Monforte, A. Antinori, E. Girardi. for the ICONA Foundation Study Group; G. Nunnari, **G.F. Pellicanò**. AIDS (IF: 4,632). **2021** Jan 29. doi: 10.1097/QAD.0000000000002825. PMID: 33534204. NLM Unique ID: 8710219. ISSN: 1473-5571. SCOPUS: 2-s2.0-85106069568. WOS:000680438100011.

49. *Pre-cART inflammation, microbial translocation and Long-Term probability of clinical progression in people living with HV*. E. Merlini, A. Cozzi-Lepri, A. Castagna, S. Lo Caputo, S. Carrara, E. Quiros Roldan, M. A. Ursitti, A. Antinori, A. d'Arminio Monforte, G. Marchetti. for the ICONA Foundation Study Group; G. Nunnari, **G.F. Pellicanò**. BMC Infectious Disease. **2021**. Doi: 10.21203/rs.3.rs-153102/v1. ISSN: 1471-2334.

48. *HBcAb positivity increases the risk of severe hepatic fibrosis development in HIV-HCV-positive subjects from the ICONA Italian cohort of HIV-infected patients*. V. Malagnino, C. Cerva, A. Cingolani, F. Ceccherini Silberstein, A. Vergori, G. Cuomo, C.F. Perno, M. Puoti, A. D'Arminio Monforte, A. Cozzi-Lepri, M. Andreoni, L. Sarmati for the ICONA Foundation Study Group; G. Nunnari, **G.F. Pellicanò**. Open Forum Infectious Dideases **2021**, 8(1) 1-8. Doi: 10.1093/ofid/ofaa566. Janvier **2021**. EISSN: 2328-8957. PMID: 33447635. PMCID: PMC7781466. WOS:000610004000018. SCOPUS: 2-s2.0-85100308809.

47. *Human Immunodeficiency Virus Continuum of Care in 11 European Union Countriern at the End of 2016 Overall and by Key Population: Have We Made Progress?* Georgia Vourli, Teymur Noori, Anastasia Pharris, Kholoud Porter, Maria Axelsson, Josip Begovac, Françoise Cazein, Dominique Costagliola, Susan Cowan, Sara Croxford, Antonella d'Arminio Monforte, Valerie Delpech, Asunción Díaz, Enrico Girardi, Barbara Günsenheimer-Bartmeyer, Victoria Hernando, Gisela Leierer, Florence Lot, Olivier Nunez, Niels Obel, Eline Op de Coul, Dimitra Paraskeva, Stavros Patrinos, Peter Reiss, Daniela Schmid, Anders Sonnerborg, Barbara Suligoi, Virginie Supervie, Ard van Sighem, Robert Zangerle, Giota Touloumi ; the European HIV Continuum of Care Working Group: Giuseppe Nunnari, **Giovanni Francesco Pellicanò**. Clinical Infectious Diseases. 31 december **2020**; 71(11):2905-16. (IF: 20,999). DOI: 10.1093/cid/ciaa696. ISSN: 1058-4838. eISSN: 1537-6591. PMCID: PMC7778352. PMID: 32960957. SCOPUS: 2-s2.0-85099326635. WOS:000607829500021.

46. *Impact of multi-drug resistance on mortality: a multi-cohort Italian study*. R. Gagliardini, A. Cozzi-Lepri, M. Zazzi, A. Tavelli, M. Santoro, D. Armenia, A. Castagna, W. Gennari, S. Rusconi, C. Mussini, P. Laghetti, CF. Perno, A. d'Arminio Monforte, A. Antinori on behalf of ICONA Founfation Study Group, G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 5-8 October

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

2020 – Comunicazione Orale O323 pag. 8-9. Abstract Supplement HIV Glasgow **2020**. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY **2020**, 23(S7):e25616. (IF: 6,707). eISSN: 1758-2652. doi: 10.1002/jia2.25616. <http://onlinelibrary.wiley.com/doi/10.1002/jia2.25616/full>. SCOPUS: 2-s2.0-85092548080.

45. *Awareness and perception of accuracy of the Undetectable=Untransmittable (U=U) message in people living with HIV/AIDS (PLWHA), in Italy and correlation with the level of confidence in reference physicians.* A. Cingolani, A. Tavelli, GV. Calvino, F. Maggiolo, E. Girardi, A. Cozzi-Lepri, A. Perziano, A. Camposeragna, R. Gagliardini, S. Nozza, A. Antinori, A. d'Arminio Monforte on behalf of ICONA Foundation Study Group, G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 5-8 October 2020 – Poster P103. Abstract Supplement HIV Glasgow 2020. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY **2020**, 23(S7):e25616 pag. 91-92. eISSN: 1360-0451. ISSN: 0954-0121. doi: 10.1080/09540121.2022.2074960. <http://onlinelibrary.wiley.com/doi/10.1002/jia2.25616/full>. PMID: 35579404. NLM Unique: 101478566. WOS:000796912700001.

44. *Durability of F/TAF-based regimens in a large cohort of PLWH seen of care in Italy.* A. Vergori, A. Cozzi-Lepri, N. Gianotti, A. Calcagno, G. Guaraldi, G. Orofino, MC. Moioli, I. Gentile, L. Sarmati, S. Cicalini, A. D'Arminio Monforte, A. Antinori on behalf of ICONA Foundation Study Group, G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 5-8 October 2020 – Poster P056 pag. 59-61. Abstract Supplement HIV Glasgow **2020**. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY **2020**, 23(S7). eISSN: 1758-2652. doi: 10.1002/jia2.25616. <http://onlinelibrary.wiley.com/doi/10.1002/jia2.25616/full>. SCOPUS: 2-s2.0-85092548080.

43. *Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected in individuals with viral load <=50 copies/ml: does eGFR matter?* A. Vergori, R. Gagliardini, N. Gianotti, A. Gori, M. Lichtner, A. Saracino, A. De Vito, A. Cascio, A. Di Biagio, A. d'Arminio Monforte, A. Antinori, and A. Cozzi Lepri on behalf of the ICONA Foundation Study Network: G. Nunnari, **G.F. Pellicanò**. International Journal of Antimicrobial Agents. **2020** Sep 9:106154. (IF: 15,441). Doi: 10.1016/j.ijantimicag.2020.106154. PMID: 32919008. SCOPUS: 2-s2.0-85091710501. WOS:000596387600037.

42. *Factors associated with hospital admission for COVID-19 in HIV patients.* Di Biagio A. E. Ricci, L. Calza, N. Squillace, B. Menzaghi, S. Rusconi, G. Orofino, O. Bargiacchi, C. Molteni, L. Valsecchi, g. cenderello, S. Ferrara, A. Saracino, P. Maggi, K. Falasca, L. Taramasso, P. Bonfanti, for the CISAI Study Group: G. Nunnari, **G.F. Pellicanò**. AIDS (IF: 4,632), **2020** Aug 10. Doi: 10.1097/QAD.0000000000002663. PMID: 32796214. NLM Unique ID: 8710219. ISSN: 1473-5571. SCOPUS: 2-s2.0-85092682143. WOS:000619185600018.

41. *Evaluation of the effect of protective genetic variants on cART success in HIV-1-infected patients.* Lori E.M., Cozzi Lepri A., Tavelli A., Mercurio V., Ibba S.V., Lo Caputo S., Castagna A., Gori A., Marchetti G., Venditti C., Clerici M., D'Arminio Monforte A., Biasin M. for the ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. J Biol Regul Homeost Agents. July/Aug **2020**; 34(4). (IF: 2,843). Doi: 10.23812/19-527-L. PMID: 32748605. NLM Unique ID: 8809253. ISSN: 0393-974X. WOS:000572821400044. SCOPUS: 2-s2.0-85096025812.

40. *Bone safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort.* Bonfanti P., De Vito A., Ricci E., Menzaghi B., Orofino G., Squillace N., Molteni C., De Socio G.V.; Salomoni E., Celesia B.M., Dentone C., Colombo V., Madeddu G. CISAI Study Group: G. Nunnari, **G.F. Pellicanò**.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Infection and Drug Resistance. 14 July **2020**;13: 2291-2300. Doi: 10.2147/IDR.S260449. (IF: 4,177). ISSN: 1178-6973. PMID: 32765005. PMC7368553. WOS:000548717000001. SCOPUS: 2-s2.0-85088563814.

39. *Evaluation of HIV transmission clusters among natives and foreigners living in Italy.* L. Fabeni, M.M. Santoro, P. Lorenzini, S. Rusconi, N. Gianotti, A. Costantini, L. Sarmati, A. Antinori, F. Ceccherini Silberstein, A. d'Arminio Monforte, A. Saracino, E. Girardi, for the ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. Viruses 2020, 12(8), 791; 23 Jul **2020**, (IF: 5,818). doi: 10.3390/v12080791. PMID: 32718024. ISSN 1999-4915. WOS:000579573600001. SCOPUS: 2-s2.0-85088812438.

38. *Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalCONA foundation cohorts.* Rossotti R., Tavelli A., Bonora S., Cingolani A., Lo Caputo S., Saracino A., Soria A., Marinaro L., Uberti-Foppa C., Mussini C., Puoti M., D'Arminio Monforte A. on behalf of the Icona Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. Dig Liver Dis. 52(4); 447-451. **2020** Jan 17. Pii: S1590-8658(19)30954-5. (IF: 5,165). doi: 10.1016/j.dld.2019.12.007. PMID: 31959479. ISSN: 1590-8658. eISSN: 1878-3562. NLM Unique ID: 100958385. SCOPUS: 2-s2.0-85077997598. WOS:000525340300012.

37. *Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort.* A. D'Arminio Monforte, A. Tavelli, A. Cozzi-Lepri, A. Castagna, S. Passerini, D. Francisci, A. Saracino, F. Maggiolo, G. Lapadula, E. Girardi, C.F. Perno, A. Antinori on behalf of the Icona Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. Journal of Antimicrobial Chemotherapy. 75(3) 681-689. 2019 Dec 22. Published: **2020** mar 01. (IF: 5,758). PMID: 31865395. NLM Unique ID: 7513617. Doi: 10.1093/jac/dkz512. ISSN: 0305-7453. eISSN: 1460-2091. SCOPUS: 2-s2.0-85079344553. WOS:000518550200026.

36. *Incidence and risk for liver enzyme elevation among naïve HIV-1 infected patients receiving ART in the ICONA cohort.* L. Taramasso, P. Lorenzini, A. Di Biagio, M. Lichtner, G. Marchetti, R. Rossotti, G. Lapadula, A. Cozzi-Lepri, F. Vichi, A. Antinori, S. Bonora, A. D'Arminio Monforte, ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. J. Antimicrobial Chemother. **2019** Aug 27. (IF: 5,758). Pii:dkz353. Doi: 10.1093/jac/dkz353. PMID: 31504633. ISSN: 1460-2091. SCOPUS: 2-s2.0-85073584650. WOS:000498167700025

35. *Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudina/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients.* F. Olearo, H. NNguyen, F. Bonnet, S. Yerly, G. Wander, M. Stoexkle, M. Cavassini, A. Scherrer, D. Costagliola, P. Schmid, H. F. Gunthard, E. Bernasconi, J. Boeni, A. D'Arminio Monforte, M. Zazzi, B. Rossetti, D. Neau, P. Bellecave, B. Rijnders, P. Reiss, F. Wit, R. Kouyos, A. Calmy, we acknowledge member of the ICONA Group: G. Nunnari, **G.F. Pellicanò**. Open Forum Infectious Diseases. 6(10) OCT **2019**. (IF: 4,423). Doi: 10.1093/ofid/ofz330. PMID: 31660328. ISSN: 2328-8957. SCOPUS: 2-s2.0-85073566350. WOS:000510164000004.

34. *Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co.infection: data from the ICONA Foundation Cohort Study.* S. Leone, P. Lorenzini, A. Cozzi-Lepri, G. Orofino, D. Bernacchia, A. Castagna, M. Menozzi, G. Guaraldi, G. Madeddu, A. Di Biagio, M. Puoti, A. D'Arminio Monforte, ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. Eur J. Clin Microbiol Infected Dis. **2019**

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Jun 22;1-9. (IF: 5,103). Doi: 10.1007/s10096-019-03618-8. ISSN: 1435-4373. PMID: 31230205. WOS:000488949500009. SCOPUS: 2-s2.0-85067867334.

33. *Is the rate of virological failure to cART continuing to decline in recent calendar years?* S. Rusconi, M.M. Santoro, N. Gianotti, A. Antinori, S. Bonora, A. Cingolani, F. Ceccherini-Silberstein, A. Tavelli, A. D'Arminio Monforte, A. Cozzi-Lepri, for the ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. Journal of Clinical Virology 116 (2019) 23-28. (IF: 14,481). Doi: 10.1016/j.jcv.2019.04.009. ISSN: 1386-6532, eISSN: 1873-5967. PMID: 31075548. IDS: IB4LQ. WOS:000470243900006. SCOPUS: 2-2.0-85065134698.

32. *Very high pre-therapy viral load is a predictor of virological rebound in HIV-1 infected patients starting a modern first-line regimen.* Armenia D., Di Carlo D., Cozzi-Lepri A., Calcagno A., Borghi V., Gori C., Bertoli A., Gennari W., Bellagamba R., Castagna A., Latini A., Pinnetti C., Cicalini S., Saracino A., Lapadula G., Rusconi S., Castelli F., Di Giambenedetto S., Andreoni M., Di Perri G., Antinori A., Mussini C., Ceccherini-Silberstein F., Monforte AD., Perno CF., Santoro MM., ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. Antivir Ther. (IF: 1,679). 24(5). 321-331. 2019 Apr 12. Doi: 10.3851/IMP3309. PMID: 30977466. ISSN: 2040-2058/1359-6535. SCOPUS: 2-s2.0-85076066134. WOS:000525652500001.

31. *Road to HCV elimination in HIV/HCV coinfecting patients by screening and universal access to DAA: baseline data from the first screening of NOCO (NO COINFECTION) study.* A. d'Arminio Monforte, A. Tavelli, A. Cozzi Lepri., S. Cicalini, A. Calcagno, R. Rossotti, E. Grilli, F. Bai, E. Quiros-Roldan, E. Girardi, A. Antinori, M. Puoti for the NoCo Study of the ICONA cohort on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. 17th European AIDS Conference (EACS) 2019 – Basilea (CH) 6-9 novembre 2019 - SESSIONE POSTER- PE37/30. HIV MEDICINE Vol. 20 (9); p. 301-302. (IF: 3,094). ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300694.

30. *Long term response to mandatory anti-HBV vaccination: risk for disease acquisition and opportunities for re-vaccination within the ICONA cohort.* R. Rossotti, A. Saracino, P. Lorenzini, C. Alcantarini, A. Latini, G. Lapadula, S. Nozza, L. Sarmati, E. Girardi, A. Castagna, A. d'Arminio Monforte, M. Puoti, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. 17th European AIDS Conference (EACS) 2019– Basilea (CH) 6-9 novembre 2019 - SESSIONE POSTER- PE37/36. HIV MEDICINE Vol. 20 (9); p. 304-305. ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300700.

29. *Comparative neuropsychiatric toxicity profile of dolutegravir versus efavirenz versus other antiretroviral third drugs used either in first-line or switching antiretroviral therapies (ART): data from ICONA Foundation Study Cohort.* A. Mondì, A. Cozzi-Lepri, A. Cingolani, A. Tavelli, M. Puoti, V. Barocci, A. Londero, F. Bai, C. Pinnetti, P. Cinque, A. d'Arminio Monforte, A. Antinori on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. 17th European AIDS Conference (EACS) 2019 – Basilea (CH) 6-9 novembre 2019 - SESSIONE POSTER- PE32/10. HIV MEDICINE Vol. 20 (9); p. 278. (IF: 3,094). ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300633.

28. *Change of prevalence, disease distribution and factors associated with the risk of AIDS presentation in Italy over last decade (2009-2018).* A. Antinori, A. Mondì, P. Lorenzini, A. Cozzi-Lepri, A. Cingolani, F. Maggiolo, A. Saracino, A. Bandera, G. Marchetti, C. Mussini, E. Girardi, A. d'Arminio Monforte, on behalf of ICONA

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. 17th European AIDS Conference (EACS) 2019– Basilea (CH) 6-9 novembre **2019** - SESSIONE POSTER- PE29/28. HIV MEDICINE Vol. 20 (9); p. 255-256. ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300577. SCOPUS: 2-s2.0-85060759242.

27. *HIV-DNA levels, HLA-B*27 and HLA-DRB*13 among LTNP, ECs and HIV controllers*. A. Gabrieli, L. Galli, M. Tarkowski, C. De Giuli, A. Saracino, G. Marchetti, S. Bonora, E. Lattuada, M. Mena, A. d'Arminio Monforte, A. Castagna, A. Riva, S. Rusconi, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. 17th European AIDS Conference (EACS) 2019 – Basilea (CH) 6-9 novembre **2019** - SESSIONE POSTER- PE26/10. HIV MEDICINE Vol. 20 (9); p. 232. (IF: 3,094). ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300514.

26. *Low Body Mass Index (BMI) in ART naïve HIV-positive subjects and risk of virologic failure and drug discontinuation: data from the ICONA Foundation cohort*. R. Rossotti, G. Guaraldi, A. Cozzi-Lepri, V. Spagnuolo, S. Cicalini, J. Vecchiet, E. Quiros Roldan, G. Madeddu, S. Lo Caputo, A. Antinori, M. Puoti, A. d'Arminio Monforte, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. 17th European AIDS Conference (EACS) **2019**– Basilea (CH) 6-9 novembre 2019 - SESSIONE POSTER- PE9/80. HIV MEDICINE Vol. 20 (9); p. 150-151. (IF: 3,094). ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300317.

25. *Determinants of switching to TAF-based cART or dual combinations (DC) from TDF-based regimens in a cohort of HIV-infected individuals with controlled viral load <50 copies/mL*. A. Vergori, R. Gagliardini, N. Gianotti, A. Gori, M. Lichtner, A. Saracino, A. De Vito, A. Cascio, A. Di Biagio, A. d'Arminio Monforte, A. Antinori, A. Cozzi Lepri, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. 17th European AIDS Conference (EACS) 2019 – Basilea (CH) 6-9 novembre **2019** - SESSIONE POSTER- PE2/62. HIV MEDICINE Vol. 20 (9); p. 85-86. ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300162.

24. *Well-Being in people living with HIV/AIDS (PLWHA): data from ICONA cohort*. A. Cingolani, J. Romaine, A. Tavelli, F. Maggiolo, M. Camici, F. Bai, S. Rusconi, A.M. Cattelan, A. Antinori, R. Cauda, A. d'Arminio Monforte, C. Bradley, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. EACS 2019 – Basilea (CH) 6-9 novembre **2019** - SESSIONE POSTER- PE2/53. HIV MEDICINE Vol. 20 (9); p. 79-80. (IF: 3,094). ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300153.

23. *Virological outcomes of first line regimens in women living with HIV from ICONA cohort: comparison with clinical trials data*. C. Mussini, P. Lorenzini, A. Cingolani, M. Lichtner, S. Di Giambenedetto, A.M. Cattelan, M. Malena, G. d'Ettore, A. d'Arminio Monforte, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. EACS 2019 – Basilea (CH) 6-9 novembre **2019** - SESSIONE POSTER- PE2/52. HIV MEDICINE Vol. 20 (9); p. 78-79. (IF: 3,094). ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300152.

22. *Effect of simplification to INSTI-based dual therapy on residual inflammation and viral reservoir*. E. Merlini, A. Cozzi-Lepri, C. Alteri, R. Scutari, A. Cingolani, F. Bai, F. Petroni, S. Lo Caputo, A. Antinori, C.F. Perno, A. D'Arminio Monforte, G. Marchetti, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. EACS 2019 – Basilea (CH) 6-9 novembre **2019** - SESSIONE POSTER- PE2/43. HIV MEDICINE Vol. 20 (9); p. 74-75. (IF: 3,094). ISSN: 1464-2662; eISSN: 1468-1293. WOS:000494690300143. SCOPUS: 2-s2.0-8505893078.

21. *Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting*. D'Arminio Monforte A., Cozzi-Lepri A., Di Biagio A., Marchetti G., Lo Caputo S., Rusconi S., Gianotti N.,

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Mazzotta V., Mazzarello G., Costantini A., Castagna A., Antinori A. and of Icona Foundation Study Group* - G. Nunnari, **G.F. Pellicanò**. J Antimicrob Chemother. Volume 74, Issue 5, May **2019** – Pag. 1363-1367. 2019 Jan 29. (IF: 5,758). doi: 10.1093/jac/dky566. ISSN 0305-7453. PMID: 30698801. WOS:000482043300031. SCOPUS: 2-s2.0-85069892134.

20. *Effectiveness of dolutegravir-based regimens as either first-line or switch antiretrovirals therapy: data from the Icona cohort*. Mondì A., Cozzi-Lepri A., Tavelli A., Rusconi S., Vichi F., Ceccherini-Silberstein F., Calcagno A., De Luca A., Maggio F., Marchetti G., Antinori A. D'Arminio Monforte A. and of Icona Foundation Study Group* - G. Nunnari, **G.F. Pellicanò**. Journal of the International AIDS Society **2019**, 22(1)e25227. (IF: 6,707). D2018i: 10.1002/jia2.25227. ISSN: 11570/3133749. PMID: 30663278. ISSN: 1758-2652. WOS:000457705500008. SCOPUS: 2-s2.0-85060137518.

19. *Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014*. D'Arminio Monforte A., Diaz-Cuervo H., De Luca A., Maggiolo F., Cingolani A., Bonora S., Castagna A., Girardi E., Antinori A., Lo Caputo S., Guaraldi G., Cozzi-Lepri A., on behalf of the ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. HIV Medicine **2019** 20(2);99-109 – February 2019. PMID: 30461158. Doi: 10.1111/hiv.12683. WOS:000455794800004. SCOPUS: 2-s2.0-85059827887.

18. *Pre-ART HIV-1 DNA in CD4+T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART*. F. Ceccherini-Silberstein, A. Cozzi Lepri, C. Altieri, E. Merlini, M. Surdo, G. Marchetti, M.R. Capobianchi, A. Dec Luca, N. Gianotti, P. Viale, A. Andreoni, A. Antinori, C.F. Perno and A. D'Arminio Monforte on behalf of the ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. J Antimicrobial Chemother; **2018** Sep 20, Vol. 73, Issue 9; (IF: 5,758). doi:10.1093/jac/dky350. ISSN: 0305-7453. eISSN: 1460-2091. SCOPUS: 2-s2.0-85056244503. WOS:000452916600031.

17. *Genotype 3 Infection in HIV/HCV co-infected in the DAA era: Real life data from the ICONA/HepalICONA Foundation cohorts*. R. Rossotti, P. Lorenzini, M. Merli, A. Castagna, A. De Luca, A. Antinori, M. Chiamenti, I. Mastroi Rosa, G. Verucchi, F. Maggiolo, A.D. Monforte, M. Puoti, for ICONA Foundation Study Group - G. Nunnari, **G.F. Pellicanò**. The International Liver Congress 2018 (EASL) – Paris, 11-15 April 2017. Poster THU-378. Journal of Hepatology **2018** vol. 68(1), 299-300. (IF: 30,083). Doi: 10.1016/S0168-8278(18)30818-3. WOS:000461068601210.

16. *Safety and efficacy of Daclatasvir at doses than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalICONA Foundation cohorts*. R. Rossotti, A. Tavelli, S. Bonora, A. Cingolani, S. Lo Caputo, A. Saracino, G. Lapadula, L. Marinaro, C. Uberti-Foppa, C. Mussini, M. Puoti, A.D. Monforte for ICONA Foundation Study Group - G. Nunnari, **G.F. Pellicanò**. The International Liver Congress 2018 (EASL) – Paris, 11-15 April 2017. Poster THU-379. Journal of Hepatology **2018** vol. 68(1), 300. (IF: 30,083). Doi: 10.1016/S0168-8278(18)30819-5. WOS:000431068601211.

15. *The Hepatitis C continuum of care among HIV infected individuals in the ICONA study network*. E. Girardi, M. Puoti, C. Mussini, A. Tavelli, I. Mastroi Rosa, F. Ceccherini-Silberstein, G. Madeddu, C. Molteni, P. Nasta, A. Antinori, A. D'Arminio Monforte, A. Cozzi-Lepri for ICONA Foundation Study Group - G. Nunnari, **G.F.**

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

Pellicanò. The International Liver Congress 2018 (EASL) – Paris, 11-15 April 2017. Poster THU-379. Journal of Hepatology **2018** vol. 68(1), 178. (IF: 30,083). Doi: 10.1016/S0168-8278(18)30568-3. WOS:000461068600351.

14. *Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment.* M. Borderi, G. Angarano, A. Antinori, A. Chirianni, P. Cianque, A. D'Arminio Monforte, A. Di Biagio, G. Di Perri, M. Galli, A. Gori, A. Lazzarin, C. Mussini, C.F. Perno, T. Quirino, G. Rizzardini, L. Calza, P. Viale, B. Accone, M. Andreoni, Acknowledgements: **G.F. Pellicanò.** New Microbiologica. 41(2), 112-117, **2018.** ISSN: 1121-7138. PMID: 29806690. WOS:000441335400004. SCOPUS: 2-s2.0-85048388111.

13. *Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project.* Bagella P., De Socio GVL., Ricci E., Menzaghi B., Martinelli C., Squillace N., Maggi P., Orofino G., Calza L., Carenzi L., Belesia B.M., Penco G., Di Biagio A., Valsecchi L., Vichi F., Colombo V., Parruti G., Dentone C., Falasca K., Bonfanti P., Madeddu G. On behalf of the C.I.S.A.I. Study Group, Italy: G. Nunnari, **G.F. Pellicanò.** INFECTION AND DRUG RESISTANCE. **2018**(11), p. 615-623, (IF: 4,177). doi: 10.2147/IDR.S152090. ISSN: 1178-6973. PubMedID: 29731650. WOS:000431435200001. SCOPUS: 2-s2.0-85046365752.

12. *Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.* C. Dentone, A. Di Biagio, A. Cozzi Lepri, D. Fenoglio, G. Filaci, M. Lichtner, S. Carrara, A. Giacometti, L. Sighinolfi, G. Marchetti, A. Antinori, A. D'Arminio Monforte, for the ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò.** HIV Clinical trials, 19(4), **2018;** p. 158-162. (IF: 1,821). Doi: 10.1080/15284336.2018.1488453. PMID: 30422095. WOS:000455697400005. SCOPUS: 2-s2.0-85057344067.

11. *Impact of CMV on liver progression in HIV/HCV/CMV coinfecting patients in a large cohort of HIV-infected patients.* S. Vita, P. Lorenzini, M. Lichtner, G. Marchetti, C.M. Mastroianni, A. Bandera, A. Di Biagio, C. Pinnetti, A. Calcagno, A. Castagna, A. Antinori, A. D'Arminio Monforte on behalf of ICONA Foundation Study Group. – G. Nunnari, **G.F. Pellicanò.** From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October 2018 – Poster P228. Abstract Supplement HIV Glasgow **2018.** JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). (IF: 6,707). ISSN: 1758-2652. doi: 10.1002/jia2.25187. ISSN: 1758-2652. SCOPUS: 2-s2.0-85055614577. WOS:000448482200265.

10. *Incidence of dyslipidemia and modification of atherosclerotic cardiovascular disease (ASCVD) risk in HIV-infected patients who switch away from tenofovir disoproxil fumarate (TDF)-based to TDF-sparing regimens in the ICONA Foundation Cohort.* S. Cicalini, P. Lorenzini, A. Cozzi Lepri, F. Maggiolo, n. Gianotti, S. Rusconi, G. Lapadula, O. Cirioni, A. Castagna, C. Mussini, S. Lo Caputo, A. Antinori on behalf of ICONA Foundation Study Group - G. Nunnari, **G.F. Pellicanò.** From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P167. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). (IF: 6,707). ISSN: 1758-2652. doi: 10.1002/jia2.25187. SCOPUS: 2-s2.0-85055614577. WOS:000448482200204.

9. *Incidence and determinants of antiretroviral switching away from TDF-based backbone in the recent years in the ICONA Foundation Cohort.* A. Vergori, P. Lorenzini, A. Cozzi Lepri, F. Maggiolo, G. Lapadula, A. De Luca, A. Cingolani, M. Galli, G. Mazzarello, P. Milini, A. D'Arminio Monforte, A. Antinori on behalf of ICONA Foundation Study Group. – G. Nunnari, **G.F. Pellicanò.** From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P100. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). (IF: 6,707). ISSN: 1758-2652. doi: 10.1002/jia2.25187. SCOPUS: 2-s2.0-85055614577. WOS:000448482200137.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

8. *Reason for choosing darunavir/ritonavir 600/100 mg BID vs. 800/100 mg QD in ART-naïve patients.* A. Tavelli, M. Palma, S. Lo Caputo, G. Madeddu, P. Bonfanti, B. Menzaghi, S. Nozza, A. Antinori, R. Termini, A. D'Arminio Monforte for the ICONA Foundation Study – G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P056. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). (IF: 6,707). ISSN: 1758-2652. doi: 10.1002/jia2.25187. ISSN: 1758-2652. SCOPUS: 2-s2.0-85055614577. WOS:000448482200094.

7. *Increased total and LDL cholesterol plasma levels upon direct antiviral agents (DAAs) driven HCV eradication.* G. Taliani, G. Marchetti, A. Cingolani, M. Lichtner, S. Cicalini, E. Quiros Roldan, M. Ursitti, E. Girardi, A. Antinori, M. Puoti, A. D'Arminio Monforte, A. Cozzi.Lepri Antinori for the ICONA Foundation Study – G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P245. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). (IF: 6,707). ISSN: 1758-2652. . doi: 10.1002/jia2.25187. SCOPUS: 2-s2.0-85055614577. WOS:000448482200281

6. *Long-term follow-up of HIV-HBV co-infected patients according to the use anti-HBV active drugs.* A. Calcagno, C. Alessandro, A. Saracino, A. De Luca, E. Colella, A. Cingolani, L. Sarmati, F. Ceccherini-Silberstein, A. Antinori, M. Puoti, C. Perno, A. D'Arminio Monforte, on behalf of ICONA Foundation Study Group: G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – O324. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). ISSN: 1758-2652. doi: 10.1002/jia2.25187. SCOPUS: 2-s2.0-85055614577. WOS:000448482200032.

5. *Health status and Quality of life in people living with HIV (PLWH): results from the ICONA cohort.* A. Cingolani, J. Romaine, A. Tavelli, F. Maggiolo, E. Girardi, A. Antinori, A. Cascio, A.M. Cattelan, A. De Luca, M. Murray, A. D'Arminio Monforte, C. Bradley on behalf of ICONA Foundation study group – G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P213. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). doi: 10.1002/jia2.25187. (IF: 6,707). ISSN: 1758-2652. SCOPUS: 2-s2.0-85055614577. WOS 000448482200250.

4. *Determinants of switching to two-drug combinations with HIV-RNA <50 copies/mL in a cohort of HIV-infected seen for care in Italy.* A. Cozzi-Lepri, H. Diaz-Cuervo, N. Gianotti, G. Lapadula, A. De Luca, F. Maggiolo, S. Rusconi, N. Bobbio, V. Esposito, M.C. Moioli, G. Madeddu, A. Antinori, A. D'Arminio Monforte for the ICONA Foundation Study Group – G. Nunnari, **G. F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P068. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). (IF: 6,707). ISSN: 1758-2652. doi: 10.1002/jia2.25187. SCOPUS: 2-s2.0-85055614577. WOS:000448482200106.

3. *Determinants of switching to TAF-based cART or two-drug combinations with HIV.RNA <50cp/mL in a cohort of HIV-infected individuals seen for care in Italy.* A. Cozzi.Lepri, A. D'Arminio Monforte, A. Capetti, A. De Luca, A. Castagna, D. Bernacchia, M. Zaccarelli, A. Cingolani, C. Mussini, C. F. Perno, A. Antinori for the ICONA Foundation Study – G. Nunnari, **G.F. Pellicanò**. From Tenth International Congress on Drug Therapy in HIV Infection – Glasgow, UK 28-31 October **2018** – Poster P070. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY 21(8). ISSN: 1758-2652. doi: 10.1002/jia2.25187. SCOPUS: 2-s2.0-85055614577. WOS:000448482200108.

Pellicanò Giovanni Francesco

Elenco delle Pubblicazioni

2. *Reason for choosing darunavir/ritonavir 600/100 mg BID vs. 800/100 mg QD in ART-naïve patients.* A. Tavelli, M. Palma, S. Lo Caputo, G. Madeddu, P. Bonfanti, B. Menzaghi, S. Nozza, A. Antinori, R. Termini, A. D'Arminio Monforte, for the ICONA Foundation Study G. Nunnari, **G. F. Pellicanò (2018)**. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. Vol.: 21(8) OCT 2018. ISSN: 1758-2652. In: abstract hiv drug therapy. p. 50, GLASGOW (UK), 28-31 OCTOBER 2018. WOS:000448482200094. SCOPUS: 2-s2.0-85055614577.

1. *Predictors of access and response to DAA in a cohort of human immunodeficiency virus/hepatitis C virus co-infected patients in Italy.* A. D'Arminio Monforte, A. Antinori, A. Cozzi-Lepri, F. Ceccherini-Silberstein, A. Castagna, S. Lo Caputo, C. Mussini, A. De Luca, G. Madeddu, A. Cingolani, A. Tavelli, G. Taliani, A. Gori, E. Girardi, M. Puoti and ICONA Foundation Study Group. G. Nunnari, **G.F. Pellicanò**. The International Liver Congress TM2017 – 52nd Annual meeting of the European Association for the Study of the Liver, Amsterdam (NL) 19-23 April 2017. Poster THU-226. Journal of Hepatology **2017** vol. 66(1), 288. Doi: 10.1016/S0168-8278(17)30893-0.

Messina 26 aprile 2023

In fede
